<SEC-DOCUMENT>0001213900-25-062404.txt : 20250709
<SEC-HEADER>0001213900-25-062404.hdr.sgml : 20250709
<ACCEPTANCE-DATETIME>20250709170045
ACCESSION NUMBER:		0001213900-25-062404
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20250709
DATE AS OF CHANGE:		20250709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACTELIS NETWORKS INC
		CENTRAL INDEX KEY:			0001141284
		STANDARD INDUSTRIAL CLASSIFICATION:	COMMUNICATIONS EQUIPMENT, NEC [3669]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				522160309
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288590
		FILM NUMBER:		251114181

	BUSINESS ADDRESS:	
		STREET 1:		4039 CLIPPER COURT
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-545-1040

	MAIL ADDRESS:	
		STREET 1:		4039 CLIPPER COURT
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>ea0248365-s1_actelis.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 21:58:54 UTC 2025 -->
<html xmlns:asns="http://www.actelis.com/20250331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the United States Securities
and Exchange Commission on July 9, 2025.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b><br/>
FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-2975">S-1</ix:nonNumeric><br/>
REGISTRATION STATEMENT<br/>
UNDER<br/>
THE SECURITIES ACT OF 1933</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-36"><b>Actelis Networks, Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact Name of Registrant as Specified in Its
Charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-47"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="white-space: nowrap; width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3669</b></span></td> <td style="white-space: nowrap; width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>52-2160309</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State or Other Jurisdiction of<br/> Incorporation or Organization)</i></span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Primary Standard Industrial <br/> Classification Code Number)</i></span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S.&#160;Employer<br/> Identification Number)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actelis Networks, Inc.<br/>
4039 Clipper Court<br/>
Fremont, CA 94538<br/>
(510)&#160;545-1045</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tuvia Barlev<br/>
Chief Executive Officer and Chairman of the Board of Directors<br/>
Actelis Networks, Inc.<br/>
4039 Clipper Court<br/>
Fremont, CA 94538<br/>
(510)&#160;545-1045<br/>
</b><i>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Copies to:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Eyal Peled, Esq.<br/>
Greenberg Traurig LLP<br/>
One Vanderbilt Avenue,<br/>
New York, New York 10017<br/>
Phone: (212) 801-9210<br/>
Fax: (212) 801-6400</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Approximate date of commencement
of proposed sale to the public: </b>As soon as practicable after the effective date of this registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act&#160;of&#160;1933
check the following box. &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is filed to
register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is a post-effective
amendment filed pursuant to Rule&#160;462(c)&#160;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Form is a post-effective
amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange&#160;Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 25%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&#160;accelerated&#160;filer</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&#160;filer</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-left: 9pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-149"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated&#160;filer</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&#160;reporting&#160;company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-156"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&#160;growth&#160;company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-164"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-2976">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The Registrant hereby
amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file
a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of
the Securities Act&#160;of&#160;1933, as amended, or until the Registration Statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The information in this preliminary
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an
offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></p><div>

</div><p style="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="color: Red; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="color: Red; vertical-align: top">
    <td style="color: Red; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRELIMINARY PROSPECTUS</b></span></td>
    <td style="color: Red; white-space: nowrap; width: 1%">&#160;</td>
    <td style="color: Red; width: 69%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBJECT
    TO COMPLETION DATED JULY 9, 2025</b></span></td></tr>
  </table><div>
</div><p style="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actelis Networks, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>6,617,897 Shares of Common Stock</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the resale, from time to time, by the selling stockholders identified herein (the &#8220;Selling Stockholders&#8221;) of up to 6,617,897
shares of common stock of Actelis Networks, Inc., par value $0.0001 per share (the &#8220;Common Stock&#8221;), consisting of (a) an
aggregate of 1,626,019 unregistered shares of Common Stock (the &#8220;Shares&#8221;), (b) up to an aggregate of 1,626,019 shares of
Common Stock that are issuable upon exercise of an unregistered long-term&#160;warrant (the &#8220;Series A-3 Warrant&#8221;), (c) up
to an aggregate of 3,252,038 shares of Common Stock that are issuable upon exercise of an unregistered short-term&#160;warrant (the &#8220;Series
A-4 Warrant,&#8221; and together with the Series A-3 Warrant, the &#8220;Common Warrants&#8221;), and (d) up to 113,821 shares of Common
Stock that are issuable upon the exercise of certain private placement warrants (the &#8220;Placement Agent Warrants&#8221;, together
with the Series A-3 Warrant, and the Series A-4 Warrant, the &#8220;Warrants&#8221;) issued to designees of H.C.&#160;Wainwright&#160;&amp;
Co., LLC, our placement agent (the &#8220;Placement Agent&#8221;) pursuant to an engagement letter in connection with the Purchase Agreement
and the offering contemplated thereunder. The shares of Common Stock and the Common Warrants were issued and sold to certain accredited
investors in a private placement that closed on July 2, 2025, as further described below under &#8220;Prospectus Summary &#8212; Recent
Developments &#8212; July 2025 Private Placement.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not selling any common
stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of shares by any of the selling
stockholders, however, we will receive proceeds from the exercise of any Warrants for cash.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
or its transferees, pledgees, assignees, or successors-in-interest may offer and sell or otherwise dispose of the shares of common stock
described in this prospectus from time to time through public or private transactions at prevailing market prices, at prices related
to prevailing market prices or at privately negotiated prices. The selling stockholder will bear all commissions and discounts, if any,
attributable to the sales of shares. We will bear all other costs, expenses, and fees in connection with the registration of the shares.
See &#8220;Plan of Distribution&#8221; beginning on page 14 for more information about how a selling stockholder may sell or dispose
of the shares of Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on the Nasdaq Capital Market under the symbol &#8220;ASNS.&#8221; On July 7, 2025, the closing price of our common stock on the Nasdaq
Capital Market was $0.58 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Investing in our securities
involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well as the information
incorporated herein and therein by reference carefully before you make your investment decision. See &#8220;Risk Factors&#8221; beginning
on page 5 of this prospectus.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 91%">&#160;</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#via_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">ii</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#via_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">iii</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#via_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: bottom"><a href="#via_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">5</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><a href="#via_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">6</td></tr>
  <tr>
    <td style="vertical-align: bottom"><a href="#via_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">7</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><a href="#via_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Offered
    Securities</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">9</td></tr>
  <tr>
    <td style="vertical-align: bottom"><a href="#via_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">14</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><a href="#via_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">15</td></tr>
  <tr>
    <td style="vertical-align: bottom"><a href="#via_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">15</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><a href="#via_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More
    Information</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">15</td></tr>
  <tr>
    <td style="vertical-align: bottom"><a href="#via_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain
    Information by Reference</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">16</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABOUT THIS PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context indicates
otherwise, references in this prospectus to &#8220;Actelis,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the
Company,&#8221; &#8220;our company&#8221; and similar terms refer to Actelis Networks, Inc., a Delaware corporation. Actelis has a wholly-owned
subsidiary, Actelis Networks Israel, Ltd, an Israeli company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The selling stockholders
named in this prospectus may from time to time sell the securities described in the prospectus. You should read this prospectus together
with the more detailed information regarding our company, our Common stock, and our financial statements and notes to those statements
that appear elsewhere in this prospectus and any applicable prospectus supplement together with the additional information that we incorporate
in this prospectus by reference, which we describe under the heading &#8220;Where You Can Find More Information.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained in, or incorporated by reference in, this prospectus and in any accompanying prospectus supplement. We have not
authorized anyone to provide you with different information from that contained in, or incorporated by reference in, this prospectus.
You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the
date on the front of those documents or that any document incorporated by reference is accurate as of any date other than its filing
date. You should not consider this prospectus to be an offer or solicitation relating to the securities in any jurisdiction in which
such an offer or solicitation relating to the securities is not authorized. Furthermore, you should not consider this prospectus to be
an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified to do so, or if it
is unlawful for you to receive such an offer or solicitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and the documents
incorporated by reference herein contain certain &#8220;forward-looking statements&#8221; within the meaning of the Private Securities
Litigation Reform Act&#160;of&#160;1995, Section&#160;27A of the Securities Act&#160;of&#160;1933, as amended (the &#8220;Securities
Act&#8221;), and Section&#160;21E of the Securities Exchange&#160;Act&#160;of&#160;1934, as amended (the Exchange&#160;Act&#8221;). We
have tried, whenever possible, to identify these forward-looking statements using words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221;
&#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;potential,&#8221;
&#8220;ongoing,&#8221; and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These
statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements
involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to
differ materially from those expressed in, or implied by, such statements. Forward-looking statements contained herein include, but are
not limited to, statements about:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
history of losses and need for additional capital to fund our operations and our ability to obtain additional capital on acceptable terms,
or at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to protect our intellectual property and continue to innovate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
success in retaining or recruiting, or changes required in, our officers, key employees or directors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
potential insufficiency of our disclosure controls and procedures to detect errors or acts of fraud;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
accuracy of our estimates regarding expenses, future revenues, and capital requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
success of competing products or technologies that are or may become available;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to grow the business due to the uncertainty resulting from the COVID-19 pandemic or any future pandemic;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to comply with complex and increasing regulations by governmental authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to regain and maintain compliance with continued listing requirements of the Nasdaq Capital Market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to continue as a going concern;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements
as to the impact of the political and security situation in Israel on our business, including due to the number of armed conflicts between
Israel and Hamas (an Islamist militia and political group in the Gaza Strip), Hezbollah (an Islamist militia and political group in Lebanon)
and Iran;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
public securities&#8217; potential liquidity and trading; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are based on our management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in
which we operate and our management&#8217;s beliefs and assumptions, and are not guarantees of future performance or development and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of
our forward-looking statements herein may turn out to be inaccurate. Important factors that may cause actual results to differ materially
from current expectations include, among other things, those listed under &#8220;Risk Factors,&#8221; &#8220;Use of Discussion and Analysis
of Financial Condition and Results of Operations,&#8221; &#8220;Business&#8221; and elsewhere herein or by incorporation by reference.
Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. You should read thoroughly
this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different
from and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
included in this prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances
reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update
or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however,
review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus.
See &#8220;Where You Can Find More Information.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
April 19, 2023, we effected a reverse stock split of our
shares of common stock at the ratio of 1-for-10. Unless indicated otherwise by the context, all common stock, option, warrant and per
share amounts, as well as share prices appearing in this prospectus (or incorporated by reference herein) have been adjusted to give
retroactive effect to the stock split for all periods presented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<a id="via_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This summary highlights
information contained elsewhere in this prospectus. Because this is only a summary, it does not contain all of the information that may
be important to you. You should read this entire prospectus and the information incorporated by reference herein, including, among other
things, the matters set forth under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and our consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal
year ended December 31, 2024 before making your investment decision. This prospectus contains forward-looking statements and information
relating to Actelis Networks, Inc. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; on page iii of this prospectus</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actelis Networks, Inc. (&#8220;Actelis,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; &#8220;our company&#8221;) is a market leader in cyber-hardened,
rapid-deployment networking solutions for wide-area IoT applications including federal, state and local government, intelligent traffic
systems (&#8220;ITS&#8221;), military, utility, rail, telecom and campus applications. Our unique portfolio of hybrid fiber, environmentally
hardened aggregation switches, high density Ethernet devices, advanced management software and cyber-protection capabilities, unlocks
the hidden value of essential networks, delivering safer connectivity for rapid, cost-effective deployment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our networking solutions
use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines which our patented technology can upgrade
to Fiber-grade to jointly create what we believe to be a highly cost-effective, secure, and quick-to-deploy network. Our patent protected
hybrid fiber networking solutions deliver excellent communication over fiber to locations that may be easy to reach with new fiber. However,
for locations that are difficult, or too costly to reach with fiber, we can upgrade existing copper lines to deliver cyber-hardened,
high-speed connectivity without needing to replace the existing copper infrastructure with new fiber. We believe that such hybrid fiber
copper networking solution has distinct advantages in most real-life installations, while providing significant budget savings and accelerating
deployment of modern IoT networks, as based on our experience, most IoT projects have challenging, hard to reach with fiber locations
which may explode such projects&#8217; timeline and budgets. We believe that our solutions can provide connectivity over either fiber
or copper with speeds of up to multi-Gigabit communication, while supporting Fiber-grade reliability and quality.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A primary focus of ours is
to provide our customers with a cyber-secure network solution. We currently offer Triple-Shield protection of data delivered with coding,
scrambling and encryption of the network traffic. We also provide secure, encrypted access to our network management software, and are
working to further enhance system-level and device-level software protection. We are also working to introduce additional capabilities
for network-wide cyber protection software as an additional SW and license-based services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When high speed, long reach,
reliable and secure connectivity is required, network operators usually resort to using wireline communication over physical communication
lines such as fiber, coax, and copper, rather than wireless communication that is more limited in performance, reliability, reach and
security. However, new fiber wireline infrastructure is costly to deploy, involves lengthy civil works to install, and, based on our
internal calculations, often accounts for more than 50% of total cost of ownership (ToC) and time to deploy wide-area IoT projects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Providing new fiber connectivity
to hard-to-reach locations is especially costly and time-consuming, often requiring permits for boring, trenching, and right-of-way,
sometimes done over many miles. Connecting such hard-to-reach locations may cause significant delays and budget overruns in IoT projects.
Our solutions aim to solve these challenges by instantly enhancing performance of such existing copper and coax infrastructure to fiber-grade
performance, through the use of advanced signal processing and unique, patented network architecture, without the need to run new fiber
to hard-to-reach locations; thus, effectively accelerating deployment of many IoT projects, as we estimate, sometimes from many months
to only days. The result for the network owner is a hybrid network that optimizes the use of both new Fiber (where available) as well
as upgraded, fiber-grade copper and coax that is now modernized, digitized and cyber-hardened. This unique hybrid network approach is
making IoT projects often significantly more affordable, fast to deploy and predictable to plan and budget.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our solutions
can also provide power over existing copper and coax lines to remotely power up network elements and IoT components connected to them
(like cameras, small cell and Wi-Fi base stations sensors etc.). Connecting power lines to millions of IoT locations can be costly and
very time consuming as well (similar to data connectivity, for the same reason &#8212; need for civil works). By offering the ability
to combine power delivery over the same existing copper and coax lines that we use for high-speed data, we believe our solutions are
solving yet another important challenge in connecting hard-to-reach locations. We believe that combining communication and power over
the same existing lines is particularly important to help connect many fifth generation, or 5G, small cells and Wi-Fi base stations,
as high cost of connectivity and power is often slowing their deployment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding: 5pt; border: Black 1.5pt solid; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, our
business was focused on serving telecommunication service providers, also known as Telcos, to provide connectivity for enterprises and
residential customers. Our products and solutions have been deployed with more than 100 telecommunication service providers worldwide,
in enterprise, residential and mobile base station connectivity applications. In recent years, as we have further developed our technology
and introduced additional products, we turned our focus on serving the wide-area IoT, federal and DoD markets, as well as multi-dwelling
units, and introduced, in 2024, our cyber-aware networking solutions for IoT markets as well.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>July 2025 Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
June 30, 2025, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain accredited investors
(the &#8220;Investors&#8221;), pursuant to which we agreed to issue and sell to the Investors in a private placement (the &#8220;July
2025 Private Placement&#8221; or the &#8220;Offering&#8221;) (a) 1,626,019 shares of Common Stock, (b) Series A-3 warrants to purchase
up to 1,626,019 shares of Common Stock, and (c) Series A-4 Warrants to purchase up to 3,252,038 shares of Common Stock, for a purchase
price of $0.615 per share and related Common Warrants, for a total aggregate gross proceeds of approximately $1 million. The July 2025
Private Placement closed on July 2, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Series A-3 Warrants have an exercise price of $0.615 per share, are exercisable commencing on the effective date of shareholder approval
(the &#8220;Shareholder Approval Date&#8221;) of the issuance of the shares issuable upon exercise of the Common Warrants (&#8220;Shareholder
Approval&#8221;) and expire five years following the Shareholder Approval Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Series A-4 Warrants have an exercise price of $0.615 per share, are exercisable commencing on the Shareholder Approval Date and expire
eighteen months following the Shareholder Approval Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the terms of the Common Warrants, the Selling Stockholders may not exercise the warrants to the extent such exercise would cause the
Investor, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed
4.99% (or, at such Investor&#8217;s option upon issuance, 9.99%), of the Company&#8217;s then outstanding Common Stock following such
exercise, excluding for purposes of such determination shares of Common Stock issuable upon exercise of such warrants which have not
been exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding: 5pt; border: Black 1.5pt solid; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">H.C.
Wainwright &amp; Co., LLC acted as the Placement Agent for the issuance and sale of the Securities. The Company has agreed to pay up
to an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Offering. The Company also agreed to pay
the Placement Agent $35,000 for non-accountable expenses and a management fee equal to 1.0% of the gross proceeds raised in the Offering.
The Company also agreed to issue to the Placement Agent, or its designees, Placement Agent Warrants to purchase up to 7.0% of the aggregate
number of the shares of Common Stock sold to the Investors (or warrants to purchase up to 113,821 shares of Common Stock) at an exercise
price per share of $0.7688 which will be exercisable commencing on the Shareholder Approval Date and a have term of five years after
the Shareholder Approval Date (the &#8220;July 2025 Placement Agent Warrants,&#8221; and collectively with the Common Warrants, the &#8220;July
2025 Warrants&#8221;). The July 2025 Placement Agent Warrants and the shares of Common Stock issuable upon exercise thereof, will be
issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving
a public offering and in reliance on similar exemptions under applicable state laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Nasdaq Listing Compliance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 25, 2023, we received
a notification letter from the Listing Qualifications Staff (the &#8220;Staff&#8221;) of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
indicating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) due to our failure to maintain a minimum of $2,500,000 in
shareholders&#8217; equity (the &#8220;Minimum Shareholders&#8217; Equity Requirement&#8221;) or any alternatives to such requirement.
In order to maintain our listing on the Nasdaq Capital Market, we submitted a plan of compliance addressing how we intended to regain
compliance. On March 27, 2024, we received a delist determination letter from Nasdaq advising us that the Staff had determined to delist
our securities from Nasdaq due to non-compliance with the Minimum Shareholders&#8217; Equity Requirement, unless we timely request a
hearing before the Nasdaq Hearings Panel (the &#8220;Panel&#8221;). We timely requested a hearing before the Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 27, 2024, we received
formal written notice from Nasdaq confirming that we have evidenced compliance with all applicable criteria for continued listing on
Nasdaq as set forth in Nasdaq Listing Rule 5550, including the Minimum Shareholders&#8217; Equity Requirement. In accordance with Nasdaq
Listing Rule 5815(d)(4)(B), we will remain subject to a panel monitor for equity compliance through August 27, 2025. As of the date of
this filing, we believe that we are not in compliance with the Minimum Shareholders&#8217; Equity Requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 20, 2024, Nasdaq notified
us that we were not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), which requires
our common stock to maintain a minimum bid price of $1.00 per share. On June 20, 2024, we received a letter from Nasdaq that, for the
10 consecutive business days from June 5, 2024 to June 28, 2024, the closing bid price of the Company&#8217;s common stock had been at
$1.00 per share or greater. Accordingly, we have regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior
bid price deficiency matter now closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on May 12, 2025,
Nasdaq notified us (the &#8220;Notification Letter&#8221;) that we were not in compliance with the minimum bid set forth in Nasdaq Listing
Rule 5550(a)(2), which requires our common stock to maintain a minimum bid price of $1.00 per share. The Notification Letter has no immediate
effect on the listing or trading of our common stock on Nasdaq and, at this time, the common stock will continue to trade on Nasdaq under
the symbol &#8220;ASNS&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notification Letter provides
that we have 180 calendar days, or until November 10, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance,
our common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If we do not
regain compliance by November 10, 2025, an additional 180 days may be granted to regain compliance, so long as we meet certain listing
criteria. If we do not qualify for the second compliance period or fail to regain compliance during the second 180-day period, then Nasdaq
will notify us of its determination to delist our common stock, at which point we will have the opportunity to appeal the delisting determination
to a Hearings Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding: 5pt; border: Black 1.5pt solid; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of common stock currently outstanding</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 62%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,211,797 shares of common stock.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities offered by the selling stockholders</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 6,617,897 shares of the Company&#8217;s common stock, par value $0.0001 per share, consisting of: (i) up to 1,626,019 shares of our common stock, (ii) up to 1,626,019 shares of our common stock issuable upon exercise of Series A-3 Warrants, (iii) 3,252,038 shares of common stock issuable upon exercise of Series A-4 Warrants, and (iv) 113,821 shares of Common Stock issuable upon the exercise of the July 2025 Placement Agent Warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock to be Outstanding Assuming Exercise of the Warrants</b></span></td>
    <td>&#160;</td>
    <td>15,829,694 shares of Common Stock. &#160; &#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling Stockholders</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the shares of our common stock are being offered by the selling stockholders. See &#8220;Selling Stockholders&#8221; on page 7 of this prospectus for more information on the selling stockholders.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan of Distribution</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The selling stockholders will determine when and how they will sell the common stock covered by this prospectus. See the &#8220;Plan of Distribution&#8221; section of this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Proceeds</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any proceeds from the sale of the Common Stock by the selling stockholders. All net proceeds from the sale of the Common Stock covered by this prospectus will go to the selling stockholders. However, we may receive the proceeds from any exercise of warrants if the selling stockholders do not exercise their warrants on a cashless basis, if and when exercised. See the section of this prospectus titled &#8220;Use of Proceeds.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Factors </b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &#8220;Risk Factors&#8221; and other information appearing elsewhere in this prospectus for a discussion of factors you should carefully consider before deciding whether to invest in our securities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listings</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ASNS.&#8221;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise indicated, all information in
this prospectus (i) assumes no exercise of the outstanding warrants described above, and (ii) gives retroactive effect to the 1-for-10
reverse stock split effected on April 19, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Delaware
in 1998. We completed our initial public offering on May 17, 2022, and our common stock is currently listed on the Nasdaq Global Select
Market under the symbol &#8220;ASNS.&#8221; Our principal executive offices are located at 4039 Clipper Court, Fremont, CA 94538, and
our telephone number is (510)-545-1040. The information contained on our website and available through our website is not incorporated
by reference into and should not be considered a part of this prospectus, and the reference to our website in this prospectus is an inactive
textual reference only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="via_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our securities
involves a high degree of risk. You should carefully consider the risk factors set forth in our most recent Annual Report on Form 10-K
on file with the SEC, which is incorporated by reference into this prospectus, as well as the following risk factors, which supplement
or augment the risk factors set forth in our Annual Report on Form 10-K. Before making an investment decision, you should carefully consider
these risks as well as other information we include or incorporate by reference in this prospectus. The risks and uncertainties not presently
known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and
could result in a complete loss of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Sales of substantial
amounts of our Common Stock by a selling stockholder, or the perception that these sales could occur, could adversely affect the price
of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sale by the selling stockholders
of a significant number of shares of Common Stock could have a material adverse effect on the market price of our Common Stock. In addition,
the perception in the public markets that the selling stockholder may sell all or a portion of its shares as a result of the registration
of such shares for resale pursuant to this prospectus could also in and of itself have a material adverse effect on the market price
of our Common Stock. We cannot predict the effect, if any, that market sales of those shares of Common Stock or the availability of those
shares of Common Stock for sale will have on the market price of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not selling any Common
Stock under this prospectus and we will not receive any proceeds from the sale of the Common Stock by the selling stockholders. All net
proceeds from the sale of the Common Stock covered by this prospectus will go to the selling stockholders. We expect that the selling
stockholders will sell their Common Stock as described under &#8220;Plan of Distribution.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may receive proceeds from
the exercise of the Common Warrants to the extent that these warrants are exercised for cash by the selling stockholders. Warrants, however,
are exercisable on a cashless basis under certain circumstances. If all of the Warrants mentioned above were exercised for cash in full,
the gross proceeds would be approximately $3.09 million. We intend to use the net proceeds of such warrant exercise, if any, for general
corporate purposes. Pending such uses, we intend to invest the net proceeds in bank deposits. We can make no assurances that any of the
warrants will be exercised, or if exercised, that they will be exercised for cash, the quantity which will be exercised or in the period
in which they will be exercised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="via_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SELLING STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
being offered by the selling stockholders are those shares of common stock issuable upon exercise of the July 2025 Warrants, and July
2025 Placement Agent Warrants previously issued in connection with the July 2025 Private Placement. For additional information regarding
the issuance of those shares of common stock and warrants, see &#8220;Prospectus Summary &#8212; Recent Developments &#8212; July 2025
Private Placement&#8221; above. We are registering the shares of common stock in order to permit the selling stockholders to offer the
shares of common stock for resale from time to time. Other than with respect to the Placement Agent, which acted as our placement agent
in the July 2025 Private Placement, a warrant inducement which occurred in July 2024 (the &#8220;July 2024 Warrant Inducement&#8221;),
a warrant inducement which occurred in June 2024 (the &#8220;June 2024 Warrant Inducement&#8221;), our December 2023 private placement
(the &#8220;December 2023 Private Placement&#8221;) and our May 2023 Private Placement (the &#8220;May 2023 Private Placement&#8221;),
each as more fully described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 as filed with the SEC on March
24, 2025, except for the ownership of the warrants issued to the Placement Agent, and the shares of common stock issued and issuable
pursuant to prior financings, the selling stockholders have not had any material relationship with us within the past three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the
selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders.
The second column lists the number the shares of common stock beneficially owned by each selling stockholder, based on its ownership
of the shares of common stock, including shares underlying the Warrants, as of July 7, 2025, assuming exercise of the Warrants held by
the selling stockholders on that date, without regard to any limitations on conversions or exercises. The third column lists the maximum
number of the shares of common stock being offered in this prospectus by the selling stockholders. The fourth and fifth columns list
the amount of the shares of common stock owned after the offering, by number of the shares of common stock and percentage of outstanding
the shares of common stock (assuming for the purpose of such percentage, 9,211,797 shares outstanding as of July 7, 2025) assuming in
both cases the sale of all of the shares of common stock offered by the selling stockholders pursuant to this prospectus, and without
regard to any limitations on conversions or exercises.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Warrants
issued in the July 2025 Private Placement, a selling stockholder may not exercise the warrants to the extent such exercise would cause
such selling stockholder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed 4.99%
or 9.99%, as applicable, of our then outstanding shares of common stock following such exercise, excluding for purposes of such determination
shares of common stock not yet issuable upon exercise of the warrants and the placement agent warrants which have not been exercised.
The number of shares does not reflect this limitation. The selling stockholders may sell all, some or none of their shares of common
stock or the Warrants in this offering. See &#8220;Plan of Distribution.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of selling stockholder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of <br/> Shares of <br/> Common&#160;Stock<br/> Owned <br/> Prior to<br/> Offering</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Maximum <br/> Number of <br/> Shares of <br/> Common&#160;Stock<br/> to be Sold <br/> Pursuant<br/> to this<br/> Prospectus</td><td style="padding-bottom: 1.5pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Shares Beneficially<br/> Owned After Offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt"><sup>&#160;</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Anson Investments Master Fund LP<sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">1,626,020</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;<sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">1,626,020</td><td style="width: 1%; text-align: left"><sup>&#160;(2)</sup>&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"><sup>&#160;</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">*</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Bristol Investment Fund, Ltd.<sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,626,020</td><td style="white-space: nowrap; text-align: left">&#160;<sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,626,020</td><td style="text-align: left">&#160;<sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intracoastal Capital LLC<sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,252,036</td><td style="white-space: nowrap; text-align: left">&#160;<sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,252,036</td><td style="text-align: left">&#160;<sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Michael Vasinkevich<sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,196</td><td style="white-space: nowrap; text-align: left">&#160;<sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,988</td><td style="text-align: left">&#160;<sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189,208</td><td style="white-space: nowrap; text-align: left">&#160;<sup>(10)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Noam Rubinstein<sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,800</td><td style="white-space: nowrap; text-align: left">&#160;<sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,854</td><td style="text-align: left">&#160;<sup>(12)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,946</td><td style="text-align: left">&#160;<sup>(13)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Craig Schwabe<sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,797</td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><sup>&#160;(14)</sup>&#160;</td><td/>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,841</td><td style="text-align: left">&#160;<sup>(15)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,956</td><td style="text-align: left">&#160;<sup>(16)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Charles Worthman<sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,089</td><td style="white-space: nowrap; text-align: left">&#160;<sup>(17)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,138</td><td style="white-space: nowrap; text-align: left">&#160;<sup>(18)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,951</td><td style="text-align: left">&#160;<sup>(19)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes less than 1%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The securities are directly
    held by Anson Investments Master Fund LP (&#8220;Anson Master&#8221;). Anson Advisors Inc and Anson Funds Management LP, the Co-Investment
    Advisers of Anson Master, hold voting and dispositive power over the ordinary shares held by Anson Master. Tony Moore is the managing
    member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors
    of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these ordinary shares except to
    the extent of their pecuniary interest therein. The address of Anson Master is Maples Corporate Services Limited, PO Box 309, Ugland
    House, Grand Cayman, KY1-1104, Cayman Islands.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i) 406,505
    shares of Common Stock (ii) 406,505 shares of Common Stock issuable upon the exercise of the Series A-3 Warrants and (iii) 813,010
    shares of Common Stock issuable upon exercise of the Series A-4 Warrants. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The securities are directly
    held by Britsol Investment Fund, Ltd. (&#8220;Bristol&#8221;). Paul L. Kessler, as manager of the investment advisory firm to Bristol,
    may be deemed to have beneficial ownership of the securities reported herein that are held by Bristol. The address of Bristol is
    c/o Bristol Capital Advisors, LLC, 1090 Center Drive, Park City, UT 84098. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i) 406,505
    shares of Common Stock (ii) 406,505 shares of Common Stock issuable upon the exercise of the Series A-3 Warrants and (iii) 813,010
    shares of Common Stock issuable upon exercise of the Series A-4 Warrants.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The securities are directly
    held by Intracoastal Capital LLC (&#8220;Intracoastal&#8221;). Mitchell P. Kopin (&#8220;Mr. Kopin&#8221;) and Daniel B. Asher (&#8220;Mr.
    Asher&#8221;), each of whom are managers of Intracoastal, have shared voting control and investment discretion over the securities
    reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership
    of the securities reported herein that are held by Intracoastal. The address of Intracoastal is 245 Palm Trail, Delray Beach, FL
    33483.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i) 813,009
    shares of Common Stock (ii) 813,009 shares of Common Stock issuable upon the exercise of the Series A-3 Warrants and (iii) 1,626,018
    shares of Common Stock issuable upon exercise of the Series A-4 Warrants. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the selling stockholders
    is affiliated with H.C. Wainwright &amp; Co., LLC, a registered broker dealer with a registered address of H.C. Wainwright &amp;
    Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole voting and dispositive power over the securities held. The number
    of shares beneficially owned prior to this offering consist of shares of common stock issuable upon exercise of placement agent warrants,
    which were received as compensation. The selling stockholder acquired the placement agent warrants in the ordinary course of business
    and, at the time the placement agent warrants were acquired, the selling stockholder had no agreement or understanding, directly
    or indirectly, with any person to distribute such securities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of (i) 72,988 Placement Agent Warrants issued in the July
2025 Private Placement, (ii) 42,404 shares of common stock issuable upon exercise of warrants issued in connection with the May 2023 Private
Placement, (iii) 57,060 shares of common stock issuable upon exercise of warrants issued in connection with the December 2023 Private
Placement, (iv) 44,872 shares of common stock issuable upon exercise of warrants issued in connection with the June&#160;&#160;2024 Warrant
Inducement, and (v) 44,872 shares of common stock issuable upon exercise of warrants issued in connection with the July 2024 Warrant Inducement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of 72,988 Placement Agent Warrants issued in the July 2025
Private Placement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(10)</td>
    <td style="text-align: justify">Consists of (i) 42,404 shares of common stock issuable upon exercise
of warrants issued in connection with the May 2023 Private Placement, (ii) 57,060 shares of common stock issuable upon exercise of warrants
issued in connection with the December 2023 Private Placement, (iii) 44,872 shares of common stock issuable upon exercise of warrants
issued in connection with the June&#160;&#160;2024 Warrant Inducement, and (iv) 44,872 shares of common stock issuable upon exercise of
warrants issued in connection with the July 2024 Warrant Inducement.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of (i) 35,854 Placement Agent Warrants issued in the July
2025 Private Placement, (ii) 20,830 shares of common stock issuable upon exercise of warrants issued in connection with the May 2023 Private
Placement, (iii) 28,030 shares of common stock issuable upon exercise of warrants issued in connection with the December 2023 Private
Placement, (iv) 22,043 shares of common stock issuable upon exercise of warrants issued in connection with the June&#160;&#160;2024 Warrant
Inducement, and (v) 22,043 shares of common stock issuable upon exercise of warrants issued in connection with the July 2024 Warrant Inducement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of 35,854 Placement Agent Warrants issued in the July 2025
Private Placement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(13)</td>
    <td style="text-align: justify">Consists of (i) 20,830 shares of common stock issuable upon exercise
of warrants issued in connection with the May 2023 Private Placement, (ii) 28,030 shares of common stock issuable upon exercise of warrants
issued in connection with the December 2023 Private Placement, (iii) 22,043 shares of common stock issuable upon exercise of warrants
issued in connection with the June&#160;&#160;2024 Warrant Inducement, and (iv) 22,043 shares of common stock issuable upon exercise of
warrants issued in connection with the July 2024 Warrant Inducement.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of (i) 3,841 Placement Agent Warrants issued in the July 2025
Private Placement, (ii) 2,232 shares of common stock issuable upon exercise of warrants issued in connection with the May 2023 Private
Placement, (iii) 3,003 shares of common stock issuable upon exercise of warrants issued in connection with the December 2023 Private Placement,
(iv) 2,362 shares of common stock issuable upon exercise of warrants issued in connection with the June&#160;&#160;2024 Warrant Inducement,
and (v) 2,362 shares of common stock issuable upon exercise of warrants issued in connection with the July 2024 Warrant Inducement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of 3,841 Placement Agent Warrants issued in the July 2025
Private Placement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span>)</td>
    <td style="text-align: justify">Consists of (i) 2,232 shares of common stock issuable upon exercise
of warrants issued in connection with the May 2023 Private Placement, (ii) 3,003 shares of common stock issuable upon exercise of warrants
issued in connection with the December 2023 Private Placement, (iii) 2,362 shares of common stock issuable upon exercise of warrants issued
in connection with the June&#160;&#160;2024 Warrant Inducement, and (iv) 2,362 shares of common stock issuable upon exercise of warrants
issued in connection with the July 2024 Warrant Inducement.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span>)</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of (i) 1,138 Placement Agent Warrants issued in the July 2025
Private Placement, (ii) 661 shares of common stock issuable upon exercise of warrants issued in connection with the May 2023 Private Placement,
(iii) 890 shares of common stock issuable upon exercise of warrants issued in connection with the December 2023 Private Placement, (iv)
700 shares of common stock issuable upon exercise of warrants issued in connection with the June&#160;&#160;2024 Warrant Inducement, and
(v) 700 shares of common stock issuable upon exercise of warrants issued in connection with the July 2024 Warrant Inducement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span>)</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of 1,138 Placement Agent Warrants issued in the July 2025
Private Placement.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>(19)</td>
    <td style="text-align: justify">Consists of (i) 661 shares of common stock issuable upon exercise of
warrants issued in connection with the May 2023 Private Placement, (ii) 890 shares of common stock issuable upon exercise of warrants
issued in connection with the December 2023 Private Placement, (iii) 700 shares of common stock issuable upon exercise of warrants issued
in connection with the June&#160;&#160;2024 Warrant Inducement, and (iv) 700 shares of common stock issuable upon exercise of warrants
issued in connection with the July 2024 Warrant Inducement.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF OFFERED SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following description
is intended as a summary of our Charter and our Bylaws, each of which will become effective prior to the effectiveness of the registration
statement of which this prospectus forms a part, and which will be filed as exhibits to the registration statement of which this prospectus
forms a part, and to the applicable provisions of the DGCL. Because the following is only a summary, it does not contain all of the information
that may be important to you. For a complete description, you should refer to our Charter and Bylaws.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
may, from time to time, sell, transfer, or otherwise dispose of any or all of their shares of common stock or interests in shares of
common stock on any stock exchange, market, or trading facility on which the shares are traded or in private transactions at fixed prices,
at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the
time of sale, or at negotiated prices. This prospectus provides you with a general description of the common stock the selling stockholders
may offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Authorized Capital Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter authorizes us
to issue up to 42,803,774&#160;shares consisting of 30,000,000&#160;shares of common stock with a par value of $0.0001 per share, 2,803,774&#160;shares
of non-voting&#160;common stock with a par value of $0.0001 per share and 10,000,000&#160;shares of preferred stock with a par value
of $0.0001 per share. As of July 7, 2025, there were 54 holders of record of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of our common
stock have the following rights, preferences and privileges:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of common stock
is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Any action at a meeting
at which a quorum is present will be decided by a majority of the voting power present in person or represented by proxy, except in the
case of any election of directors, which will be decided by a plurality of votes cast. There is no cumulative voting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available for payment, subject
to the rights of holders, if any, of any class of stock having preference over the common stock. Any decision to pay dividends on our
common stock will be at the discretion of our board of directors. Our board of directors may or may not determine to declare dividends
in the future. See &#8220;Dividend Policy.&#8221; The board&#8217;s determination to issue dividends will depend upon our profitability
and financial condition any contractual restrictions, restrictions imposed by applicable law and the SEC, and other factors that our
board of directors deems relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a voluntary
or involuntary liquidation, dissolution or winding up of the Company, the holders of our common stock will be entitled to share ratably
on the basis of the number of shares held in any of the assets available for distribution after we have paid in full, or provided for
payment of, all of our debts and after the holders of all outstanding series of any class of stock have preference over the common stock,
if any, have received their liquidation preferences in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Rights and Preferences</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
have no pre-emptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our
common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected
by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. Shares of our common
stock are not convertible into shares of any other class of capital stock, nor are they subject to any redemption or sinking fund provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fully paid and nonassessable</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our outstanding shares
of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><!-- Field: Split-Segment; Name: 1 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to issue
up to 10,000,000&#160;shares of preferred stock. Our Charter authorizes the board to issue these shares in one or more series, to determine
the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations
and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per
share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series.
Our board of directors could, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect
the voting power and other rights of the holders of common stock and which could have the effect of making it more difficult for a third
party to acquire, or of discouraging a third party from attempting to acquire, a majority of our outstanding voting stock. No shares of
preferred stock are curerntly outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Charter and Bylaw Provisions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Charter and Bylaw Provisions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter and our Bylaws
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our management team, including
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Board of Directors vacancies. </i>Our Charter provides that vacancies on the board of directors may be filled only by the affirmative vote of a majority of the directors then in office, irrespective of whether there is a quorum, or by a sole remaining director. Additionally, the number of directors to serve on our board of directors is fixed solely and exclusively by resolution duly adopted by our board of directors. This would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Classified Board of Directors. </i>In accordance with our Charter, as it will be in effect following the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will be divided into three classes with staggered three-year&#160;terms. At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes. We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third&#160;of the directors. The division of our board of directors into three classes with staggered three-year&#160;terms may delay or prevent a change of our management or a change in control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Special Meetings of Stockholders. </i>Our Bylaws provide that special meetings of our stockholders may be called by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No Cumulative Voting. </i>The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless the corporation&#8217;s certificate of incorporation provides otherwise. Our Charter does not provide for cumulative voting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment of Charter and Bylaw Provisions. </i>Any amendment of our Charter requires the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, except that the provision in the Charter regarding the staggered board may not be repealed or amended without the vote of the holders of not less than 80% of the Company&#8217;s voting stock, voting as a single class. Amendments to our Bylaws may be executed pursuant to a resolution by the Board of Directors pursuant to an affirmative vote of a majority of the directors then in office, or by the affirmative vote of at least 75% of the outstanding shares of capital stock entitled to vote.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Delaware Business Combination Statute. </i>The Company is subject to the &#8220;business combination&#8221; provisions of Section&#160;203 of the DGCL.&#160;In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three&#160;years following the date such person becomes an interested stockholder, unless the business combination or the transaction in which such person becomes an interested stockholder is approved in a prescribed manner. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &#8220;interested stockholder&#8221; is a person that, together with affiliates and associates, owns, or within three&#160;years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our Board of Directors, and the anti-takeover effect includes discouraging attempts that might result in a premium over the market price for the shares of our common stock.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exclusive Forum. </i>Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, stockholder or other employees to us or our stockholders, (iii)&#160;any action asserting a claim against the Corporation or any current or former director, officer, stockholder, employee or agent of the Corporation arising pursuant to any provision of the DGCL, our Charter or our Bylaws, (iv)&#160;any action to interpret, apply, enforce or determine the validity of the Company&#8217;s Charter or Bylaws, (v)&#160;any action asserting a claim against us governed by the internal affairs doctrine or (vi)&#160;any action asserting an &#8220;internal corporate claim&#8221; as that term is defined in Section&#160;115 of the General Corporation Law. The federal district courts of the United&#160;States of America shall be the exclusive forum for the resolution of any complaint, claim or proceeding asserting a cause of action arising under the Exchange&#160;Act or the Securities Act. Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provision in our Charter. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anti-Takeover&#160;Provisions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of the DGCL,
our Charter and our Bylaws may have the effect of delaying, deferring or discouraging another person from acquiring control of our company.
These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage
persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection
of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal
to acquire us because negotiation of these proposals could result in an improvement of their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter established a
classified board of directors, divided in three classes with staggered three-year&#160;terms. Under the classified board of directors
structure, only one class of directors would be elected at each annual meeting of our stockholders, with the other classes continuing
for the remainder for their respective three-year&#160;terms. Under the classified board of directors structure: (i)&#160;directors in
Class&#160;I, consisting of Gideon Marks, are to stand for election at the Annual Meeting to be held in 2026; (ii)&#160;directors in Class&#160;II,
consisting of Joseph Moscovitz, are to stand for election at the annual meeting of stockholders to be held in 2024; and (iii)&#160;directors
in Class&#160;III, consisting of Israel Niv and Tuvia Barlev, are to stand for election at the annual meeting of stockholders to be held
in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Limitations on Liability, Indemnification of
officers and directors and insurance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter and Bylaws contain
provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL.&#160;Consequently,
our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors,
except liability for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in Section&#160;174 of the DGCL; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction from which the director derived an improper personal benefit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Listing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on the Nasdaq Capital Market under the symbol &#8220;ASNS.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent and Registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock will be VStock Transfer, LLC.&#160;The transfer agent and registrar&#8217;s address is 18 Lafayette Place, Woodmere,
NY&#160;11598.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exclusive Forum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter provides that,
unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole
and exclusive forum for any stockholder for (a)&#160;any derivative action or proceeding brought on our behalf, (b)&#160;any action asserting
a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any current or former director, officer, stockholder, employee
or agent of the Company to the Company or the Company&#8217;s stockholders, (c)&#160;any action asserting a claim against the Corporation
or any current or former director, officer, stockholder, employee or agent of the Corporation arising pursuant to any provision of the
DGCL or the Company&#8217;s Certificate of Incorporation or Bylaws, (d)&#160;any action to interpret, apply, enforce or determine the
validity of the Company&#8217;s Certificate of Incorporation or Bylaws, or (e)&#160;any action asserting a claim governed by the internal
affairs doctrine or (f)&#160;any action asserting an &#8220;internal corporate claim&#8221; as that term is defined in Section&#160;115
of the General Corporation Law. The federal district courts of the United&#160;States of America shall be the exclusive forum for the
resolution of any complaint, claim or proceeding asserting a cause of action arising under the Exchange&#160;Act or the Securities Act.
Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought
to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders cannot waive
compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring
or holding any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provision in our Charter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The choice-of-forum&#160;provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or
its directors, officers or other employees, and may result in increased costs to a stockholder who has to bring a claim in a forum that
is not convenient to the stockholder, which may discourage such lawsuits. Although under Section&#160;115 of the DGCL, exclusive forum
provisions may be included in a company&#8217;s certificate of incorporation, the enforceability of similar forum provisions in other
companies&#8217; certificates or incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could
find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive forum provision of our Charter
inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs
associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition
and results of operations and result in a diversion of the time and resources of our management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anti-Takeover&#160;Provisions of the DGCL and
Charter Provisions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain provisions of the
DGCL and certain provisions included in our Charter and Bylaws summarized below may be deemed to have an anti-takeover&#160;effect and
may delay, deter, or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including
attempts that might result in a premium being paid over the market price for the shares held by stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Removal of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide that stockholders
may only remove a director with or without cause by a vote of no less than a majority of the shares present in person or by proxy at the
meeting and entitled to vote, voting together as a single class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amendments to Certificate of Incorporation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain sections of our Certificate
of Incorporation require the affirmative vote of the holders of a majority of the voting power of the then outstanding shares of capital
stock of the Company entitled to vote, voting together as a single class, except that the provision in the Charter regarding the staggered
board may not be repealed or amended without the vote of the holders of not less than 80% of the Company&#8217;s voting stock, voting
as a single class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Staggered Board</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors is
divided into three classes, with regular three-year&#160;staggered terms. This classification system increases the difficulty of replacing
a majority of the directors and may tend to discourage a third-party&#160;from making a tender offer or otherwise attempting to gain control
of the Company. In addition, under Delaware law, the Certificate and the By-Laws, the Company&#8217;s directors may be removed from office
by the stockholders only for cause and only in the manner provided for in the Certificate. These factors may maintain the incumbency of
the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amendments to Bylaws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter limits the abilities
of the directors and stockholders to amend our Bylaws in certain circumstances. In particular, the Bylaws may be amended only by the vote
of a majority of all of the directors then in office, or by the affirmative vote of the stockholders holding at least 75% of the outstanding
shares of capital stock entitled to vote in accordance with the provisions of the Charter, Bylaws, and the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>No Cumulative Voting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter does not provide
for cumulative voting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Special Meetings of Stockholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide that, except
as otherwise required by law, special meetings of the stockholders may be called only by an officer at the request of a majority of our
board of directors, by our Chief Executive Officer or President or by the holders of not less than 25% of the holders of stock entitled
to vote at the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PLAN OF DISTRIBUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders of
the Shares and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered
hereby on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities are traded or in private
transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods
when selling securities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement of short sales;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions through broker-dealers that agree with the selling stockholder to sell a specified number of such securities at a stipulated price per security;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such methods of sale; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted pursuant to applicable law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
also sell securities under Rule&#160;144 or any other exemption from registration under the Securities Act, if available, rather than
under this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by
the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from each selling stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule&#160;2121; and in the case of a principal transaction a markup or markdown
in compliance with FINRA Rule&#160;2121.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling
stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. The selling stockholders have informed us that they do not have any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The resale securities will
be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain
states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules and
regulations under the Exchange&#160;Act, any person engaged in the distribution of the resale securities may not simultaneously engage
in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation&#160;M, prior
to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable provisions of the Exchange&#160;Act
and the rules and regulations thereunder, including Regulation&#160;M, which may limit the timing of purchases and sales of the common
stock by the selling stockholder or any other person. We will make copies of this prospectus available to the selling stockholders and
have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by
compliance with Rule&#160;172 under the Securities Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEGAL MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the shares
of the common stock offered by this prospectus will be passed upon for us by Greenberg Traurig, LLP, New&#160;York, NY.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="via_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPERTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements incorporated
in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2024 have been so incorporated in reliance
on the report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described
in Note 1b to the financial statements) of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers
International Limited, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="via_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WHERE YOU CAN FIND MORE INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed a registration
statement on Form&#160;S-1 with the SEC under the Securities Act&#160;with respect to the securities offered in this prospectus. This
prospectus, which is filed as part of a registration statement, does not contain all of the information set forth in the registration
statement, some portions of which have been omitted in accordance with the SEC&#8217;s rules and regulations. Statements made in this
prospectus as to the contents of any contract, agreement or other document referred to in this prospectus are not necessarily complete
and are qualified in their entirety by reference to each such contract, agreement or other document that is filed as an exhibit to the
registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You can read our SEC filings,
including the registration statement, over the internet at the SEC&#8217;s website. Upon completion of this offering, we will be subject
to the information reporting requirements of the Exchange&#160;Act, and we will file reports, proxy statements and other information with
the SEC.&#160;The SEC&#8217;s website contains reports, proxy and information statements and other information regarding registrants that
file electronically with the SEC.&#160;The address of that site is <i>http://www.sec.gov</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also maintain a website
at <i>www.Actelis.com</i>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>However, the information
contained in or accessible through our website is not part of this prospectus or the registration statement of which this prospectus forms
a part, and investors should not rely on such information in making a decision to purchase our common stock in this offering.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="via_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &#8220;incorporate
by reference&#8221; information into this prospectus. This means that we can disclose important information to you by referring you to
another document filed separately with the SEC. The information that we incorporate by reference is considered to be part of this prospectus.
Because we are incorporating by reference our future filings with the SEC, this prospectus is continually updated and those future filings
may modify or supersede some or all of the information included or incorporated in this prospectus. This means that you must look at all
of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously
incorporated by reference have been modified or superseded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus incorporates by reference the documents
listed below that have been previously filed with the SEC:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual Report on <a href="http://www.sec.gov/Archives/edgar/data/1141284/000101376225001251/ea0234571-10k_actelis.htm">Form 10-K</a>&#160;for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Quarterly Report on&#160;<a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390025042679/ea0241162-10q_actelis.htm">Form 10-Q</a>&#160;for quarter ended March 31, 2025 filed with the SEC on May 13, 2025;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on
    Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390025009695/ea022973301-8k_actelis.htm">February
    4, 2025</a> (as amended on <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025013541/ea0230930-8ka1_actelis.htm">February
    13, 2025</a>); <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025013574/ea0230983-8k_actelis.htm">February 13,
    2025</a>; <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025020293/ea0232994-8k_actelis.htm">March 4, 2025</a>; <a href="https://www.sec.gov/Archives/edgar/data/1141284/000101376225003599/ea0236027-8k_actelis.htm">March
    28, 2025</a>; <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025027237/ea023654901-8k_actelis.htm">April 1,
    2025</a>; <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025042695/ea0241879-8k_actelis.htm">May 13, 2025</a>;
    <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025046475/ea024307301-8k_actelis.htm">May 21, 2025</a>,&#160;<a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025054496/ea0245614-8k_actelis.htm">June 16, 2025</a> and <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025061358/ea0247801-8k_actelis.htm">July 3, 2025</a>;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our
    common stock, which is contained in the registration statement on <a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390022023871/ea159353-8a12b_actelis.htm">Form 8-A</a> filed with the SEC on May 4, 2022 (File No.
    001-41375).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incorporate by reference
all future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the SEC pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Securities Exchange Act, subsequent to the date of this prospectus and prior to the termination of the
offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different
information. Any statement contained in a document incorporated by reference into this prospectus will be deemed to be modified or superseded
for the purposes of this prospectus to the extent that a later statement contained in this prospectus or in any other document incorporated
by reference into this prospectus modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed,
except as so modified or superseded, to constitute a part of this prospectus. You should not assume that the information in this prospectus
is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information about us contained
in this prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of
any or all of these filings, at no cost, by writing or telephoning us at Yoav Efron, Chief Financial Officer and Deputy Chief Executive
Officer, 4039 Clipper Court, Fremont, CA 94538 USA, telephone number +1-510-545-1045 or by emailing us at yoave@actelis.com<span style="text-decoration:underline;text-decoration: none">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actelis Networks, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PRELIMINARY PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.75in"><b>, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART&#160;II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;13. OTHER EXPENSES OF ISSUANCE AND
DISTRIBUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the costs and expenses payable by the Company in connection with this offering. All expenses incurred with respect to the registration
of the common stock will be borne by the Company. All amounts are estimates, except the SEC registration fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">SEC registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">588</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Printing expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Legal fees and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23,588</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;14. INDEMNIFICATION OF DIRECTORS
AND OFFICERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;102(b)(7)&#160;of
the Delaware General Corporation Law (the &#8220;Delaware Law&#8221;) enables a corporation, in its original certificate of incorporation
or an amendment thereto, to eliminate or limit the personal liability of a director for monetary damages for breach of the director&#8217;s
fiduciary duty, except (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for
acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;pursuant to Section&#160;174
of the Delaware Law (providing for liability of directors for unlawful payment of dividends or unlawful stock purchases or redemptions),
or (iv)&#160;for any transaction from which the director derived an improper personal benefit. The Company&#8217;s Sixth Amended and Restated
Certificate of Incorporation, as amended (&#8220;Certificate of Incorporation&#8221;), contains such a provision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Section&#160;145
of the Delaware Law provides that a corporation may indemnify any persons, including officers and directors, who are, or are threatened
to be made, party to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or
investigative (other than an action by or in the right of the corporation), by reason of the fact that such person is or was an officer,
director, employee or agent of the corporation, or is or was serving at the request of such corporation as a director, officer, employee
or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines
and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided
such officer, director, employee or agent acted in good faith and in a manner the person reasonably believed to be in or not opposed to
the corporation&#8217;s best interests and, with respect to criminal proceedings, had no reasonable cause to believe that the person&#8217;s
conduct was unlawful. A Delaware corporation may indemnify officers or directors in an action by or in the right of the corporation under
the same conditions, except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be
liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred
to above, the corporation must indemnify him or her against expenses (including attorneys&#8217; fees) that he or she actually and reasonably
incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Certificate
of Incorporation and Restated Bylaws provide for indemnification of directors and officers to the fullest extent permitted by the Delaware
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following information
represents securities sold by the Company within the past three years which were not registered under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
June 30, 2025, we entered into the Purchase Agreement with the Investors, pursuant to which we agreed to issue and sell to the Investors
in a private placement (a) 1,626,019 shares of our Common Stock, (b) 1,626,019 Series A-3 Warrants, and (c) 3,252,038 Series A-4 Warrants,
for a purchase price of $0.615 per share and related Common Warrants, for a total aggregate gross proceeds of approximately $1 million.
The Offering closed on July 2, 2025. The Company also agreed to issue to the Placement Agent, 113,821 Placement Agent Warrants at an exercise
price per share of $0.7688.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2024, we entered
into an inducement letter with the holder of our certain warrants issued in June 2024 (&#8220;June 2024 Warrants&#8221;). Pursuant to
the inducement letter, the holder agreed to exercise for cash 999,670 of its June 2024 Warrants to purchase an aggregate of 999,670 shares
of our common stock at an exercise price of $2.00 per share, in consideration of our agreement to issue the July 2024 warrants to purchase
up to an aggregate of 1,999,340 shares of our common stock, at an exercise price of $1.75 per share. We also agreed to issue to the Placement
Agent 69,977 shares of common stock at an exercise price of $2.50 per share and a term of five and one-half years. Our total aggregate
gross proceeds were approximately $2.25 million, and the transaction closed on July 2, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 5, 2024, we entered
into an inducement letter with the holder of our warrants issued in May 2023 (&#8220;May 2023 Warrants&#8221;). Pursuant to the inducement
letter, the holder agreed to exercise for cash its May 2023 Warrants to purchase an aggregate of 999,670 shares of our common stock at
an exercise price of $2.75 per share, in consideration of our agreement to issue the June 2024 Warrants to purchase up to an aggregate
of 1,999,340 shares of our common stock, at an exercise price of $2.00 per share. We also agreed to issue to the Placement Agent 69,977
shares of common stock at an exercise price per share of $3.4375 and a term of five and one-half years. Our total aggregate gross proceeds
were approximately $3.0 million, and the transaction closed on June 6, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&#160;17, 2023,
we entered into a securities purchase agreement with an investor,&#160;pursuant to which we agreed to issue and sell to the investor in
a private placement (i)&#160;301,000 shares of our common stock, (ii) 970,187 pre-funded warrants to purchase up to 970,187 shares of
our common stock and (iii) 1,271,187 shares of common stock issuable upon the exercise of common warrants, at a purchase price of $1.18
per share of common stock and related common warrant, or $1.1799 per pre-funded warrant and related common warrant, for a total aggregate
gross proceeds of approximately $1.5 million (the &#8220;December 2023 Private Placement&#8221;).&#160; The offering closed on December&#160;20,
2023. The common warrants have an exercise price of $1.18 per share, are exercisable immediately upon issuance and expire five and one-half
years following the issuance. The pre-funded warrants were sold in lieu of shares of common stock, are exercisable immediately upon issuance,
have an exercise price of $0.0001 per share and expire when exercised in full. We also agreed to issue to the Placement Agent, 88,983
shares of common stock at an exercise price per share of $1.475 and a term of five and one-half years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 4, 2023, we entered
into a securities purchase agreement with an investor, pursuant to which we agreed to issue and sell to the Investor in a private placement
(i) 190,000 shares of our common stock, (ii) 754,670 pre-funded warrants to purchase up to 754,670 shares of our common stock and (iii)
944,670 shares of common stock issuable upon the exercise of common warrants, at a purchase price of $3.705 per share of common stock
and related common warrant, or $3.7049 per pre-funded warrant and related common warrant, for a total aggregate gross proceeds of approximately
$3.5 million. The Offering closed on May 8, 2023. Following an amendment in September 2023, the common warrants now have an exercise price
of $2.75 per share, are exercisable immediately upon issuance and expire five and one-half years following the issuance. The pre-funded
warrants were sold in lieu of shares of common stock, are exercisable immediately upon issuance, have an exercise price of $0.0001 per
share and expire when exercised in full. We also agreed to issue to the Placement Agent, 66,127 shares of common stock at an exercise
price per share of $4.6313 and a term of five and one-half years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2023, we issued
to the Placement Agent an additional 55,000 shares of common stock issuable upon the exercise of common warrants, at a purchase price
of $2.75 per share. As part of the December 2023 Private Placement, we agreed, subject to our shareholders approval, which has not yet
been obtained, to amend the exercise price of the warrants to $1.18 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities above were
offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act since, among
other things, the transactions did not involve a public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16. EXHIBITS AND FINANCIAL STATEMENT
SCHEDULES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Exhibits.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 9%; border-bottom: black 1.5pt solid; padding-right: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td>
    <td style="width: 90%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022025173/fs12022a4ex3-5_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of the Twenty-Fourth Amended and Restated Certificate of Incorporation of the Registrant, dated May 2, 2022 (as filed as Exhibit 3.5 to the Company&#8217;s Form S-1/A, filed on May 10, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022023064/fs12022a1ex3-4_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of Actelis Networks, Inc. (as filed as Exhibit 3.4 to the Company&#8217;s Form S-1/A, filed on May 10, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023024106/f10k2022ex4-1_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities (filed as Exhibit 4.1 to the Company&#8217;s Form&#160;10-K for the fiscal year ended December&#160;31, 2022, filed on March&#160;29, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022023064/fs12022a1ex4-1_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Representative&#8217;s Warrant (as filed as Exhibit 4.1 to the Company&#8217;s Form&#160;S-1/A, filed on May&#160;2, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023037340/ea178132ex4-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Warrant (as filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on May&#160;8, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023037340/ea178132ex4-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (as filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form&#160;8-K, filed on May&#160;8, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023037340/ea178132ex4-3_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant (as filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form&#160;8-K, filed on May&#160;8, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023097390/ea190433ex4-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Warrant (as filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December&#160;20, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023097390/ea190433ex4-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (as filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December&#160;20, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023097390/ea190433ex4-3_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant (as filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December&#160;20, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390024014088/ea193785ex4-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Credit Agreement (as filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, as filed on February 14, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025061358/ea024780101ex4-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A-3 Warrant (as filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on July 3, 2025)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025061358/ea024780101ex4-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A-4 Warrant (as filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on July 3, 2025)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12 </span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025061358/ea024780101ex4-3_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant (as filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on July 3, 2025)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea024836501ex5-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Greenberg Traurig LLP</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022023064/fs12022a1ex10-2_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease by and between Actelis Networks Israel, Ltd. and Moshe Smucha, dated January&#160;13, 2000 (as&#160;filed as Exhibit 10.2 to the Company&#8217;s Form&#160;S-1/A, filed on May&#160;2, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022023064/fs12022a1ex10-3_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to the Lease and Management Agreements from October&#160;22, 2017, by and between Homerton Investments, Ltd. and Actelis Networks Israel Ltd., dated April&#160;14, 2021 (as filed as Exhibit 10.3 to the Company&#8217;s Form&#160;S-1/A, filed on May&#160;2, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-9_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Actelis Networks, Inc. and Mr.&#160;Tuvia Barlev dated February&#160;15, 2015 (as filed as Exhibit 10.9 to the Company&#8217;s Form&#160;S-1/A, filed on May&#160;2, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-10_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer letter between Actelis Networks, Inc. and Mr.&#160;Yoav Efron dated November&#160;30, 2017 (as furnished as Exhibit 10.10 to the Company&#8217;s Form&#160;S-1/A, filed on May&#160;10, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022023064/fs12022a1ex10-11_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Actelis Networks Israel, Ltd. And Mr.&#160;Yoav Efron dated November&#160;30, 2017 (as furnished as Exhibit 10.11 to the Company&#8217;s Form&#160;S-1/A, filed on May&#160;10, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-12_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement between Actelis Networks, Inc. and Barlev Enterprises dated February&#160;20, 2015 (as furnished as Exhibit 10.12 to the Company&#8217;s Form&#160;S-1/A, filed on May&#160;10, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-13_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actelis Networks, Inc. 2015 Equity Incentive Plan (as filed as Exhibit 10.13 to the Company&#8217;s Form&#160;S-1, filed on April&#160;15, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-14_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to 2015 Equity Incentive Plan (as filed as Exhibit 10.14 to the Company&#8217;s Form&#160;S-1, filed on April&#160;15, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-16_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Loan Agreement between Migdalor Business Investment Fund and Actelis Networks Israel, Ltd., dated December&#160;2, 2020 (as filed as Exhibit 10.16 to the Company&#8217;s Form&#160;S-1, filed on April&#160;15, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-17_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment Number 1 to Senior Loan Agreement between Migdalor Business Investment Fund and Actelis Networks Israel, Ltd., dated November&#160;17, 2021 (as filed as Exhibit 10.17 to the Company&#8217;s Form&#160;S-1, filed on April&#160;15, 2022)</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td>
    <td style="width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390022020064/fs12022ex10-18_actelisnet.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase and Loan Repayment Agreement between Actelis Networks, Inc. and Mr.&#160;Tuvia Barlev dated April&#160;15, 2022 (as filed as Exhibit 10.18 to the Company&#8217;s Form&#160;S-1, filed on April&#160;15, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023037340/ea178132ex10-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (as filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on May&#160;8, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023037340/ea178132ex10-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement (as filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form&#160;8-K, filed on May&#160;8, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023097390/ea190433ex10-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Amendment (as filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on December 20, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023097390/ea190433ex10-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (as filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on December 20, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023097390/ea190433ex10-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Amendment (as filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on December 20, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390023097390/ea190433ex10-3_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement (as filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on December 20, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390024050213/ea020741801ex10-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Inducement Letter (as filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on June 6, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390024050213/ea020741801ex10-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of June 2024 Warrant (as filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on June 6, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390024050213/ea020741801ex10-3_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of June 2024 Placement Agent Warrant (as filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on June 6, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390024058192/ea020877201ex10-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Inducement Letter (as filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on July 2, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390024058192/ea020877201ex10-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of July 2024 New Warrant (as filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on July 2, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1141284/000121390024058192/ea020877201ex10-3_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of July 2024 Placement Agent Warrant (as filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on July 2, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390024081872/ea021488501ex10-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Market Offering Agreement, dated September 25, 2024, between the Company and H.C. Wainwright &amp; Co., LLC (as filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 25, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025061358/ea024780101ex10-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (as filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 3, 2025)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1141284/000121390025061358/ea024780101ex10-2_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement (as filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on July 3, 2025)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea024836501ex23-1_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.) a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Company</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="#via_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea024836501ex-fee_actelis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Financial Statement Schedules</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All financial statement schedules
are omitted because the information required to be set forth therein is not applicable or is included in the consolidated financial statements
or related notes incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;17. UNDERTAKINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required by section 10(a)(3)&#160;of the Securities Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;&#160;<i>provided</i>,&#160;<i>however</i>, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii)&#160;of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d)&#160;of the Exchange&#160;Act&#160;that are incorporated by reference in the registration statement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule&#160;424(b)&#160;as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1)&#160;or (4)&#160;or 497(h)&#160;under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><div><a id="via_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act&#160;of&#160;1933, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Freemont, California on July 9, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTELIS NETWORKS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tuvia Barlev</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tuvia Barlev</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Secretary</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>POWER OF ATTORNEY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL MEN BY THESE PRESENTED,
that each director and officer of Actelis Networks, Inc. whose signature appears below hereby appoints Tuvia Barlev and Yoav Efron, and
each of them severally, acting alone and without the other, his/her true and lawful attorney-in-fact with full power of substitution or
re-substitution, for such person and in such person&#8217;s name, place and stead, in any and all capacities, to sign on such person&#8217;s
behalf, individually and in each capacity stated below, any and all amendments, including post-effective -amendments to this Registration
Statement, and to sign any and all additional registration statements relating to the same offering of securities of the Registration
Statement that are filed pursuant to Rule 462(b) of the Securities Act of 1933, and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, full power and authority
to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and
purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute
or substitutes, may lawfully do or cause to be done by virtue hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 54%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Tuvia Barlev</i></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chairman of the Board of Directors</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 9, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tuvia Barlev</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <i>Yoav Efron</i></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Deputy Chief Executive Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 9, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoav Efron</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer and Principal Accounting Officer)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Niel Ransom</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 9, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Niel Ransom</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gideon Marks</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 9, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gideon Marks</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Julie Kunstler</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 9, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julie Kunstler</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-7</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>











































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-2979">0001141284</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-2980">false</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="asns-20250331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb8xOYtPeNESS0HWLdfr4iJuQUueersOTwI6y96qaPrzmCkI4XgUC/a77N1YAxjVvK6XJ/t3hMDB/1wrrY4XJfpn+ey2IRtDLOiQ3an+ekUu3nvOCQPo3clWNU1UOk3P8JKHjOSLBiaG8AsqgB0rEtd7EPVUhTI+MlsxwuUon4kN9Zm2rAYG1Wf5Vey0vui5OKjSutYuqctczWA+sVgkhMWRLucsnOr1LE9xwSArN9OX7V2jHkaavfq] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001141284</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea024836501ex5-1_actelis.htm
<DESCRIPTION>OPINION OF GREENBERG TRAURIG LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actelis Networks, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4039 Clipper Court</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fremont, CA 94538</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Actelis Networks, Inc. Registration Statement on Form S-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel for Actelis Networks, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), in connection with the preparation of a Registration Statement on Form S-1, including the prospectus
constituting a part thereof (as may be amended, the &ldquo;<U>Registration Statement</U>&rdquo;), being filed by the Company with the
Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), relating to the registration for resale under the Registration Statement of an aggregate of 6,617,897 shares (the &ldquo;<U>Registered
Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.0001 per share (&ldquo;<U>Common Stock</U>&rdquo;) which consists
of the following: (i) 1,626,019 shares of Common Stock (the &ldquo;<U>Shares</U>&rdquo;)issued in a private placement which closed on
July 2, 2025 (the &ldquo;<U>Private Placement</U>&rdquo;), (ii) 1,626,019 shares of Common Stock issuable (the &ldquo;<U>Series A-3 Warrant
Shares</U>&rdquo;) upon the exercise of Series A-3 warrants issued in the Private Placement (&ldquo;<U>Series A-3 Warrants</U>&rdquo;),
(iii) 3,252,038 shares of Common Stock <U>Series A-4 Warrant Shares</U>&rdquo;) issuable upon the exercise of Series A-4 warrants issued
in the Private Placement (&ldquo;<U>Series A-4 Warrants</U>&rdquo;) and (iv) 113,821 shares of Common Stock (&ldquo;<U>Placement Agent
Warrant Shares</U>&rdquo;, and, with the Series A-3 Warrant Shares and the Series A-4 Warrant Shares, the &ldquo;<U>Warrant Shares</U>&rdquo;)
issuable upon the exercise of placement agent warrants issued in the Private Placement (&ldquo;<U>Placement Agent Warrants</U>&rdquo;,
and, with the Series A-3 Warrants and the Series A-4 Warrants, the &ldquo;<U>Warrants</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our representation of the Company, and as a basis
for the opinions hereinafter set forth, we have examined originals, or copies certified or otherwise identified to our satisfaction, of
the following (collectively, the &ldquo;<U>Documents</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Registration Statement;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company&rsquo;s Amended and Restated Certificate of Incorporation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company&rsquo;s Amended and Restated Bylaws;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">resolutions adopted by the Company&rsquo;s Board of Directors approving, among other things, the issuance of the Shares, the Warrants and the Warrant Shares; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">such other documents and records and other certificates and instruments and matters of law as we have deemed necessary or appropriate to express the opinion set forth below, subject to the assumptions, limitations and qualifications stated herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In rendering the opinions set forth below, we have assumed: (i) the
genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals,
the conformity to original documents of all documents submitted to us as duplicates or certified or conformed copies and the authenticity
of the originals of such latter documents; (ii) each individual executing any of the Documents, whether on behalf of such individual or
another person, is legally competent and authorized to do so; (iii) each of the parties (other than the Company) executing any of the
Documents has duly and validly executed and delivered each of the Documents to which such party is a signatory; and (iv) the obligations
of each party set forth therein are legal, valid and binding obligations of such party and are enforceable against such party in accordance
with all stated terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actelis Networks, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As to matters of fact, we have relied upon the Documents and, solely
to the extent we deemed reasonably appropriate, upon representations or certificates of officers or directors of the Company, without
independently verifying the accuracy of such documents, records and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based solely upon and subject to the foregoing, and subject to the
assumptions, limitations and qualifications stated herein, we are of the opinion that the Shares are duly authorized, validly issued,
fully paid and nonassessable. Further, we are of the opinion that the Warrant Shares have been duly authorized and, when issued by the
Company upon exercise of the Warrants in accordance with the terms thereof, will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This opinion letter is limited to the matters stated herein, and no
opinions may be implied or inferred beyond the matters expressly stated herein. We assume no obligation to supplement this opinion if
any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after
the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not express any opinion herein concerning any law other than
the laws of the State of Delaware and the federal laws of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to the use of the name of our firm therein. In giving this consent, we do not admit that we are within the
category of persons whose consent is required by Section 7 of the Securities Act or the rules and regulations of the Commission promulgated
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">/s/ Greenberg Traurig, LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">GREENBERG TRAURIG, LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea024836501ex23-1_actelis.htm
<DESCRIPTION>CONSENT OF KESSELMAN & KESSELMAN, CERTIFIED PUBLIC ACCOUNTANTS (ISR.) A MEMBER FIRM OF PRICEWATERHOUSECOOPERS INTERNATIONAL LIMITED, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0 0pt"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We hereby consent to the incorporation
by reference in this Registration Statement on Form S-1 of Actelis Networks, Inc. of our report dated March 24, 2025 relating to the financial
statements, which appears in Actelis Networks, Inc.&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2024. We also consent
to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">/s/ Kesselman &amp; Kesselman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Kesselman &amp; Kesselman<BR>
Certified Public Accountants (Isr.)<BR>
A member firm of PricewaterhouseCoopers International Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Tel-Aviv, Israel<BR>
July 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ea024836501ex-fee_actelis.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actelis Networks, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 1: Newly Registered Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security<BR> Type</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security Class Title</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee<BR> Calculation<BR> Or Carry<BR> Forward<BR> Rule</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount<BR> Registered<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR> Share<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum<BR> Aggregate<BR> Offering<BR> Price<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee<BR> Rate</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<BR> Registration<BR>
    Fee</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 9%; text-align: left; padding-bottom: 0pt; text-indent: -0.125in; padding-left: 0.125in">Fees to Be Paid</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 8%; text-align: center; padding-bottom: 1.5pt">Equity</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center; padding-bottom: 1.5pt">Common Stock, $0.0001 par value per share</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%; text-align: center; padding-bottom: 1.5pt">457 (c)</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; padding-bottom: 1.5pt; text-align: right">6,617,897</TD><TD STYLE="width: 0.5%; padding-bottom: 5pt; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="width: 7%; padding-bottom: 1.5pt; text-align: right">0.58</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="width: 7%; padding-bottom: 1.5pt; text-align: right">3,841,689.21</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="width: 7%; padding-bottom: 1.5pt; text-align: right">0.0001531</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">588.17</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt">Total Offering Amounts</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">3,841,689.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">588.17</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt">Total Fees Previously Paid</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right; padding-bottom: 1.5pt">Total Fee Offsets</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right; padding-bottom: 4pt">Net Fees Due</TD><TD STYLE="padding-bottom: 4pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">588.17</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), this registration statement shall also cover any additional shares of common stock, par value $0.0001 per share (&ldquo;Common Stock&rdquo;), of Actelis Networks, Inc that may be issued in connection with a stock dividend, stock split, recapitalization or similar transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457 under the Securities Act, based on the average of the high and low prices of the Common Stock on the Nasdaq Capital market on July 7, 2025.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i) 1,626,019 shares of Common Stock issued in a private placement that closed on July 2, 2025 (the &ldquo;Private Placement&rdquo;) (ii) 1,626,019 shares of Common Stock issuable upon the exercise of Series A-3 warrants issued in the Private Placement (iii) 3,252,038 shares of Common Stock issuable upon the exercise of Series A-4 warrants issued in the Private Placement and (iv) 113,821 shares of Common Stock issuable upon the exercise of placement agent warrants issued in the Private Placement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 0T# 2(  A$! Q$!_\0
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MYX^*O@?PWH]^KZ=I4=L9.6$;N%_ 9P/PH \8FU?4[JW%M/J-W+ .D<DS,H_
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M_J)/]T_RKX,U#_D)77_79_YFOO.;_4O_ +I_E7QK=Z18M?7),')E?^-O4^]
M'I?[-'^N\1?[L'_L]:'[1&F^(K^ST^:TMFFT6V#//Y6699#P&8>@'0^YJ7X
MV=O:3:[Y$>S<(<\D_P![UKVPJ&!# $$8(/>@#X-TW5=0T:\2[TV\FM+A>DD+
ME3^G6NZ3XY>/$M/(_M2%CC'F-;(7_/%>Q?$GX>^$VT^745T2WBNSDEX2T>3Z
MD*0#^5>$KH>G&ZV&V^7=C&]O\: .5O+NZU*]EN[N:2XN9W+22.<L['O7NWPJ
M^#R7FA3:EXFMGC:Z*FVA8894&?F([9R./:NW^'7@'PK9:=#J4.BVYO.")I2T
-A4^HW$X_"O2L4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G / # 2(  A$! Q$!_\0
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M:2>]M;9E6:YAB9N@DD"D_G4E%BB@$$ @Y!JO]MM/M'V?[5#Y^<>7Y@W?EUH
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:\227]A%()/LL4"Q"4CIO(ZT45:DTB911_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>asns-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 21:58:54 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.actelis.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:asns="http://www.actelis.com/20250331" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="asns-20250331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="asns-20250331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb8xOYtPeNESS0HWLdfr4iJuQUueersOTwI6y96qaPrzmCkI4XgUC/a77N1YAxjVvK6XJ/t3hMDB/1wrrY4XJfpn+ey2IRtDLOiQ3an+ekUu3nvOCQPo3clWNU1UOk3P8JKHjOSLBiaG8AsqgB0rEtd7EPVUhTI+MlsxwuUon4kN9Zm2rAYG1Wf5Vey0vui5OKjSutYuqctczWA+sVgkhMWRLucsnOr1LFqnnz2irBOOPrH+49plV0j] CSR-->
      <link:roleType roleURI="http://www.actelis.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="asns_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>asns-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 21:58:54 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb8xOYtPeNESS0HWLdfr4iJuQUueersOTwI6y96qaPrzmCkI4XgUC/a77N1YAxjVvK6XJ/t3hMDB/1wrrY4XJfpn+ey2IRtDLOiQ3an+ekUu3nvOCQPo3clWNU1UOk3P8JKHjOSLBiaG8AsqgB0rEtd7EPVUhTI+MlsxwuUon4kN9Zm2rAYG1Wf5Vey0vui5OKjSutYuqctczWA+sVgkhMWRLucsnOr1LGpLV4IKAo6793Imwb47FHu] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>asns-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 21:58:54 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="asns-20250331.xsd#DocumentAndEntityInformation" roleURI="http://www.actelis.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.actelis.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="asns-20250331.xsd#asns_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb8xOYtPeNESS0HWLdfr4iJuQUueersOTwI6y96qaPrzmCkI4XgUC/a77N1YAxjVvK6XJ/t3hMDB/1wrrY4XJfpn+ey2IRtDLOiQ3an+ekUu3nvOCQPo3clWNU1UOk3P8JKHjOSLBiaG8AsqgB0rEtd7EPVUhTI+MlsxwuUon4kN9Zm2rAYG1Wf5Vey0vui5OKjSutYuqctczWA+sVgkhMWRLucsnOr1LEcvFgr+CVcIKBMyXNpCOgD] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001141284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Actelis Networks, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>9</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0248365-s1_actelis.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actelis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>asns-20250331.xsd</File>
    <File>asns-20250331_lab.xml</File>
    <File>asns-20250331_pre.xml</File>
    <File doctype="S-1" isOnlyDei="true" original="ea0248365-s1_actelis.htm">ea0248365-s1_actelis.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0248365-s1_actelis.htm": {
   "nsprefix": "asns",
   "nsuri": "http://www.actelis.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "asns-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "asns-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "asns-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0248365-s1_actelis.htm"
     ]
    }
   },
   "keyStandard": 9,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 12,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 9
   },
   "report": {
    "R1": {
     "role": "http://www.actelis.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248365-s1_actelis.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248365-s1_actelis.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "asns_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actelis.com/20250331",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.actelis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-25-062404-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-062404-xbrl.zip
M4$L#!!0    (  *(Z5I_D2XC800  "@,   1    87-N<RTR,#(U,#,S,2YX
M<V2]5MMRXC@0?<]7:/VT6RECFTL(5,@4(3<("4R,(<S4U)2P!5$PLJ,+MZ\?
M26 N";#,U-:^V>H^W:?5TFE=?)F.0C!&E.&(E PG91L $3\*,!F4#,\URVZE
M6C6^7 )P<O&7:8([1!"%' 6@-P.5:!2[/@8M"@GK1W0$_N:C?X )7CF/BY8U
MF4Q2OO1A/J:(18+ZB*D%8)HR8!*R0I$*6 0M@4!-A, ^!VFGF#LOYK+ :U5
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M\"QG+WLVD=[G3N*UCCS*?F5#;F\;Q&V?_/BZ+[ZQO;OQ%$^_ 5!+ P04
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MKOIS[:I_>KM;T9\>L:CJ'=R06R_=,Y+ZZ<\XMF1QO73_A2"\;RLM9EF$J#_
M%R') -6%\MF-0I24_O!9:6?UGKYTL27!S^YI?*,2&N\EE9SGO7\?XXX&):>E
M_B7MM2;G']77>JNGD?['IXS<PKE$M_^!\=>OSSY>NI>_G5S4TA)^[*#]QRA4
M:6KB6O"$J[//4\= 9[PBNIHVP6*RV 3M&1M<K6ETHZJ?Y+5GXKQ6"@G&=XXJ
MQ8^*IZO%C@CU$P#7\!,78WXISQIGUP99]EU=WM^UQ%?'/$_Q1O<&+-9POAG?
M1&!5I?D@#4:!G\R]VFO=DS3Q5>BYI]F(ZE+QWX$I(?5C0;UJ(<*9GV2(J/;;
M$N$(@7FCVA/BW+;H<0F??'RD<:RM6*C4P=(!C2 OA/[4@5XZ:<X.+U>P8LK&
M MR*C*@#APFD-%*@-H7TRD)I2HQ7V*)[!O<>67@7QECAIT7U!K.YO'=1S(D&
M,"!BX8IO'<9/SV:(XE)AJCB#KV%_\#48J(=G0RF-VPSXJ /!K<J@]O+TL5LP
M#Z=A8!OEX4GN_XTRIV AB;"-&NZ6AE4W*_NV7OIP(-MO2R"4J#:<NW%$_X.[
MZMA'AM+"9U1%1*#,$D2GA,?!!YIH2-)&V^! !2$1Q'#B7Q-(V/%S(-T$-#ZB
M0JR#3FA)*D="4!^BME% 7C L'FC-6E"Y"//^JOEW'&N?*+TV37-"@_I9%;S4
M=(4$ZM)\;1!7,@0>(\4=!#?,R L!U/A\(/P9LQY8&I;B&,O%'DF++1J+KS:^
M1#Y=M-H[C8Y8W3&A4VD2)6['"=,12,D&S#97=#;9R(CFY4QCS>A"GY!H&FRZ
M.,LXB)@-.%0.XXO>*NG1AJ@Z[EN&^2,W]HB@[KPNYXMF(&!UD$GPX-2G8%\Y
M<=I^DTSXSQQN,^5Z86Y(#,\P%8_A:!#5E$>@UR"J"=&ON AX3(/4%V[6$\.Q
MWL$,WEY;O ]L\:Y-WB6:O/W5F+Q'AQ\Q!QTS\=^?71Z[Y\>_'IZ_.7G_J_OV
M[/QW^.?FZ=G9/_%OTTOQ42WBOG7_GX >5+5>-'C9R%6G780**%E4#).*)LKH
M6' =H> Z"A5<&[*HP(A!,55^)"FQE%TGN246G/84_G/%HN%<4=/PAMI3!SM>
MN<A3?^]0O_,^5:LJ::!F$O1#.VNS/%CON&&P6@7BVM#;]:$;?J0-O=^50SIB
ME@187@O,EPASM+#*>!H,,)\:1*#D2.LB)NUGX>:46@!F_2@5@9GJA8.!6'-P
M!&&H/W-T;>;/2#O5)P<J#&!>U8\1@(]=2VKEHF&ZV,^I_@WF/46CZJ?2$T-5
M)S,+X6Y4GIUA9F1]AJE2GVJ?D0I46W73A\.F#V<Q-KH&>[0ZKSBZBF&C2PG$
MVHD#&XBMD"A!R3Z[]E/S= 5Q;9!'F"Q-)=/8,/3'XX#T<BZ; S3@6&<.5QBK
M*;*1G2=D/M!YC<7J!9L16[-3>FC)&N*'P53R,6E+ITNA&^"02LC!-$,PV(F0
MVJ>OLRW<3U%\PQD.><3_QFP+6%X>"3<QSA!6RL<,]!&CF([ '?I8#!+7 E^"
MNHAU!?(0-PET39H[,BLT1883)$G>@RQVV'9RD1RQV5ZHW2%D6,BA6(;3=!8&
MQ )E?<5Z.@;$UG#!"@M,^&5 ;:RPR$%.B=P.ZKE8THC2A$&_M5T9B"/\^6FI
MJLM%T]ZW<%P;KG9QP=P6]Z%3!\#RJE^\:OH&97?Y35B=>LG597?W#LJELU=6
M AJND /J %PP2@L.0:#(Y8N4XGJJEF-K*%EF</_'N;CCXIEB7V=J/'3^ ,SG
MC$IBQ@-.5:^_(^;6!C-)P$2GMN=P BC<R])V.!2T7%UQW?4%^+$N@$6OH!9G
M6DRB%A*BT$0!@YW58(OG1.1:$R'1'44Q*JYKBEU3[,HH5LH$H"J88%"%#2FL
M<#U,<BIM2/H+&Q2H_/V9!XG6:Y!I<[]0&.63FKN*6_-*4J'N$KHFZ#5!KX2@
MT=UOC"@@T31'Z@Q4-)SKS'>LWP"Z29Y(CFH<LK9!-4E&><)Q/\R'!=ZMD@3M
M!=+^,W+SCQ,_'ZWI>4W/*Z-GCC,5!*Q](*D5[R[*AXSS#$D[4=0M5^J):$59
MF#<9AVL:7M/PRFA8*QE<1FBF,HEBC_*AQ%[5<!+%87Q%O:EUC;HXD3+25-G?
M.(W6I+LFW<>PZ+ ##?E'!]+HR1WEIN!3X7.<BPL1:=P4.#LZ^]?)F\W>@3O#
MCN93+H*%D7IAV/KC-6VO:?LQ:)M;'3$JB.N[?!;XT3!1?BHMR/-0_'.#N7L5
MP]9'J$M@]R-&AJ"_?4W!:PI^# I&;5@*7DV1#5-0&2DY*#H3:6\;MS=FHBY4
M8AU^;:S MB;K-5D_#F,6!S&!["D,C)^!LA&M27)-DBLA22OV[J=:X0VFL,^9
MJ2(< \'BWDI960*PS-TTR'*#[^4\#PS7H1]#*]&>A+21L"U]NF@H[R>8@@ T
M/PX#-!<'*KM1*G+D=3C>;_X4)K9!N20A+!+KW.(-"GSV[9G)8;+M3,,>?O7_
MX[L761+,GGON;^H_ RR^-+G7:T[5P(_BZ#G5ZSM)_/6=7-_)U8D)*:=<P*2I
M3OK>2[?P@8<!Z#>C0**-6&D6CH$ 1&M"71/JJ@B507YB.Q9N:T'T8[O=44Y-
M#TRZ$B/WYZ3UM#8!MG*9_G'V^H):Y3XF63_9?*5V@)E30NNA7(9AI8F%<)/4
MH/SL8_2*0(2'X!XU]-/,A-+^K71)=RIE9\M[ Q*&.<*<L41LY)AS9PR0,@"@
MAMF4L(:84323"6GP(2+BKG(?&PA()Q#M9"LC^D9%BPG\[=?C"HOF*G!UT&4-
M>X*]$M0\EN5(R+'C'J(VSWY"CSLI2%7XL4.9B>V(0,$!HF,<%H5GEDF^4!#I
MG*2.>S*=Q3!5;)MH3PY_Q8C',MJ18IY50*-#WLNFPR]0B/XT1KR Y#S!5%-/
M()!H8:M1N>V'76ZM"GZ5HF%O@G28<[8J;O!AY(?S-$BQK/Q;DZYY!/O)'2GP
MF7-9 U9U,A"RZNM?"_G9$-HB@5,V%0YA,+?2OJ04AP&M=YP/5G19-TK!$\^3
M*\XRLG*?"#LMNU^4VX9A%#: \C/- ML/NRD_-J96"G Z3=F")?"]R1@U&=XF
MQ91.A?J4\R3\S(; FB B[ZNT\K20KB9OD$F$6HS *A6GO=W(L$PQE)=HV#F1
MN'L+B0\T\GQ8U'VT-N5) EI7W!YD(3R:[F9CUC;\U__$Z:J^\7>UE*L&)A4"
MN6'?#CA,0>07R9L5F4Z8<)/C[2PX79](RT_A7"GAX ;/.2HQ;1ZE3(8>J$7
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M,V8[F7_%A=JFL#.X*>%F&(Q1T4N1M>GP&E HUXR\#F@-V-LY@+U%57*0CZZ
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MY7PYRZJQS*_E6,X7<"RWQC>_ED7<,HM%+,NML:ROX*'.<GC6DR?YY?&KWI?
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MQK*^]8MX#4Y+M"6R>^ %$NWP1[A&A4H619#4R %Q6U:G*F\OK'URC)N+S3I
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M-1H:''1[U%6K>I%[);M1X4$-/QG,Z1SU -Q4@'000PBDO"% /KZ)P$9'%=X
M9$%W0FY74YU@6T4;EM 'UVE>%#-V!SGB>.,IHSA@YD&4"]44S'/%30'67/.'
MX9I'Z'$'&Q&N;9V!,ML\B4"#1[RHC[XENA=6?@2A0X("/ 5\38R, B]XI_26
M.V2=5-);6FZ4@4P%' *E:$,V293B^(*^W##>U97B$N+PY>9<^0G3 1F=P$LS
MQJ;Y480X!XU[%RQ9%70FA<#S(=BEJ3!9:U(3S&^@%S.S4I]G 8)S=0PYI-!-
MP9DYA<+*#C P,>1W)<O>S8%KA/PP66(R83W1XB#T.]C1T;YE/IB25_)":]\Z
M[N_8!V)&T1?JAX(P.R-QBA=.@EEJ<56V"2/-UTWXJ$DT%5/1M<Y;IP.BB:9!
M)!C!Z:$, GJ)@:('F.9 I\<Q)7JM5<H^CM0F;1:?>%5&<^@.MR-=S+Z_D+@D
MG%;1HWTM/NK:,R<P\;>%FKV6"VNY\#!RX4(\BN^8AQ#'OBA!;+5&S9:E5JB9
M+VA_Y-3Z-1*TS2^U0@T'$K+2V*)X(XX7/6%YDN:2U.?;NB>[X8I7?*TZCORU
M:0&UR6-8N[2 (I!=H('Y7ROL"_<=-J[YT2_C^]@]*M#<G'C %_!2DFHK]FR)
M5#4"PX:I&7@(V2S\;B5.>1'.C;!T4#5"U-_8ON%NY_",P9T.\51)+Z%K!P*_
M>*B8HTG\+ =<3*ZOYB7HBFZ"L7^#,N\QYG*_X/O..OA^O^![K_O]1M^?TM59
M2ZBG+Z$.P4@9:=M]47R&Q1:E9]D_L0LN)(K"A6FK,H>?5]6Y.J2K!B,L"4!^
M5\1]M,Q4"LC7UXUK&9ZU03G.'G$Q$7K&)(>1[.94?]DO+8R+O;GR$Q-.+XQ,
M5ILMI311,^Q91[4*:'G2_@YCV!)>-FNRHLCX:Q'P0!S[W9\JH'@CZ.U@K0GZ
M<WT4^%<HUG#'-821ZKH:8B^(]J\^JR'9^*WJO6CU#>[]TD^BK];[V;?>:D'@
MQOAIYN[M_/0U1/>TU9=;8KIK5GP;(S3<.'CUN!SYC8)KAJK_:VETB%=XH#/"
M+C(_@VM7&!%ROS'L8^&KD<@E]TSW2\2PAGZ-SC\K%_JY8+M!%[7;*A7_X4]/
M(NU-]>J/P]ND-I$/5WP0!L-PSDDR9DVV54'.115=,1@%\VC<IKGJ?HJF9(P&
MD^C $WG8P%H/XA'/.%%2G@]]=VG%G3WR=1-&,?6YN%/:/H)GVTZ-,XPY9<:J
M)X/+84_XO8:BF*'VBM".8$;R, D&"H5$!#O?<7_E \ PH7^70Q;H0$K9U,D5
M>_Y31:Y)9G6FM@S[0.QU%+Y@FDZ15LA]2 VQ-:^G/-E(S[;Y83/?E,^3>F>2
MESB+KSBPRJ2@^\)*#E2:QD/ZT\.07^IQ<E@V(0E<H852X:YRKB59O8V'@O&-
M/ 4!-,(!/+"X?C*(01)5309U&12%-U5]QN:SE&0U-@$2T190J!+6"\4A")Y-
MC=O0,1E:N42;:?YV[2(4_B6R&5U3R$?BN74);*E+38,9BBG#Q1@;)IZ**3DA
MF#P,J4Z#?%JDD-G%CNB:EB'Y#15,GH2 _1Y:I?_H9LVQ!CQ@!;E\RN+R([/Q
M&T7Q)"G_<(-]>!GN*'6O"N\97L806$+$&N68H1RL5>>)-IG@IB5&2T7Y3!?<
MB+R !0<!/TI8#'X?78R-X#D?E4_I[E2?#)\0)LQYH4.E2&$=)'&.=T]#0-3$
M#\=<>;=XB:ZA 8P^814?%?M@BE-#OP77.$2&/LJ!>\("1CGJVC>60URN:)XD
M$LC"**ZRPH^>J.#X+YMA&DD"_"*,YTJ1#9$3!JT:39""O7>8N8\PD323_2_T
M")3_F-C:.D\S3:\LUO7LZ U78M!6W^XG05J+8D1SBW=;6I)7LH=EM;JP)%8"
MKBT38>DH=8!YHA$[FZ&D5%@?<:@8LF=*#J#Q!Y=F9-E$5>/.&MF,VC!H^]["
M&5TA_XZ*J Q-#X/$('?] -/XXV&6!(R:W[A>?'1ED1]1.0+>6\4C:Z'OBUC!
MU>*5&8%R$;$T*^F9O=Z.7KRH%J73.O5O6-B.U8AKW06,E*<&X@7^^F,4@)3G
M5]*5I6_ YH5G?911',LF=WK#?17LD<E&E]1J+%,)^P@'*7>M=&]+NTYU-/%W
MPQ*549MQ>OVQX/-YCH?#3&N9%T6K>/BTX[Z%=<%=0VVDJI/W#5<J_<;%8+Z@
MEO2M^3=\GXXXI8"6J#>0@FK$U/0.HGC'_4ES5/4U-P)"UF1+3(RX"2:'2U4*
M&=20565*>E/ST"117%'XP&0XT-9T2K%,V,8(=9\;'X^'MC\HL"Z9109%PW67
MG!A:_;E]O,.BD3MF3:!38([, $Z'3JQ4#I,!\_(Q3I(OP=QHEJ5JE\Q>2TX'
M0WE8*X-]#Y(@G05#*3PTTN*KB @Q99:<3Q8C$O#;<!++.ZJ/H_9)*29E3)]A
M*_H(,6\RL=D&Z7W_SH%NT"3@U](U#K":)I8K&?O7<#>M2@BS/--0BT(@-$B4
M!B&B2RL1!$-KIF+,X:D2/5J<3$.HF]Y>)&:8US]ZI/?Q:EVB$7 I1@!/X5%2
M$YXL,/]RTE84V7/::TD75ETY@X?@0Y00-J+L&.$796,K*N$1&(AEN$L%*#MD
M-:#C7%)N6S%3?6.X" $69Z8TNX$*XQNO=7KV/(QI. A&#*Z:<])>F,:2%:=&
M'M51(V@?B0&YF8Y *(#[JD_EE")[!3EIAZ:F+3".),T*N&(3&OEWA6L(U+4J
M7._BD$@E?$UX-<HLRU@F.KI. GP ](ZBK6!KQ>C:VY1'XR10T2@D,99'&/D<
M!@1JXR50#A2%(\4]G9+9G?E2&**2:@43F<6I'SK6)L#*!U)26T^@4"CY(.DW
MDLQF6]L1EFA"@W]:Z*U!PCC%5>52/=GK:F,30.@" P_2"9Z<,RQ0LW6Z\BSD
MZ1?A3C\:[6WA. ZHI/D0"W!XG(Z *:BF@H:%J*1#MS"F?AG7:N%9ZU:548&L
M AT64#VZ<@I%%K,1M"N5Z<C*:_BZM;IFK3\75JZ-PG0(R"S>9:]2&OA7. VX
M$._\Y!/ZK!*JUD*1&RY :9"US (.>5\$^B9E'G25IGZWO_O2LI+M2;CV)$X\
MISR+?\2IFDW<=S%<Z.L@^\\=9E(_H1*RIS:S[9?2+*8^/:<ZO=HNG:2)KT+W
M?7!-+[G,KP/??>TGH;I>YE0=GNK.=Y^J>2_TS>X:?7-/]$UOC;[Y-N[!X-5I
M47< W8VGVICWL,>4FD9%)D,\=DJV53G+"RPRT(3@E-?&1#W+5XP%Z9/B5+-Z
MV3!'3EWX4G0A0+/)8XI'18JJ)H[\*2FAVCF0AR&Z'F JJ"O.T)^869X8*[R+
M7>3H/F;AG"V;2GZ'@%18L:<"L3@IKJ+6[-]MGMI8G+:%*[KDB$8_C9]:FIDC
M0)MB"^ -Z]SC=9SH:V90)D ;8U24X\WYMH7QW _95&PF\Y=/)'BY)M'OCD1]
M=H_'TR E;RWR8%#%K^(8%'J?W"2)>%VQ=.ZUDL9GDMLW13\$=H247+1/$8-A
MKH,X-/X&D$!K"EY3\ -0<!X!;8$*HFO'BX_#5'!'WYH\P2&01$ET13&4IR@O
M13J!*9!<BPSN;=N.V9?PVS5%KRGZ87BR#9$CWWS1=4[K$(SC0*^=^&IGQIU?
MP.=^W)C3*?NOU@8A&X25GM!@Z" ,4=>A?^^G(_]/TXCN'0/K"K! .I\.XE!C
M+0XOWE_H%A/?NZ]N\.I2.E-*/WBTJ,^E.D6RIBZ.7>KNG0)S$KP#[Q'% 5I;
M)/R+\!;NI6G_>7IZ),Z"VUY<P =&HP2!=T#6O7WWU!_[<Y7IINV>^SLHLE.5
M*,]Y_X<!^1SL?_=NYD$5I;BFUF?MI;X\)W\4^*:^"!K#Z;1A.$VK6BLO8<-?
M JYSL !AY]P+UFEA_&^2.+H:Q30N8?._!D#IU &4G)0BIZ+_E(!C%;58@8,.
MOP(,ZCP-,*A#J?TMRSTJI]J?E%+M;>3FZ"OAHLZM<-$[S@0I6=WE5-JPHTXC
M=G2\<NBH\R2@H\X3@8XZ3P,ZZJP(.OJCB]96Y*SSE)"SSI-"SO[H-(/\D''#
MF_%XDS:+9V5VS'DD\'!9KW"0G]P51:Q[,!5PN@(O.(Q3SG@O5S>]F2 YI2V+
M*.;N!&G1-"D*5&02)$O*QNTX9K@^(2;]7TV$L;=E07#:2472V$%DR=>7G#Y)
M*QU6-(%%Y7]8918.;46@4SCTT$^J5XB;*N">.SP*L X9QQZ&CB:H:AP#CH7C
M5@^4BK!P7A@JD&4T;VI*:LE%.4N@EZ"H'L@TY+/,8>"D@^0DF,IL/E/20J*(
MLW,_H,CJ"D9^:;/F4'7<D[%Y*35FAQ_IU]8$?4D?M/B)LW",6I*GW9I"CIOJ
MFQ'6SBQ$9X&65 9$ '+OKP %M5WLD4C<,6FS(S-L'%)35J)#W;19GV5)RAM<
M,<-2X5G@,MPN-JIW16!K1A*4O:;.I+JG!=Q&YNX@-ORBUX:=9 H,4/>PX W)
M@,_IIV"@82$?K"*,^'T#CGAEMOY*.?E]$6Q[:P3;/1%L_36"[8E?@%MR6FSA
MB<S!T2ZG==J+/07T#_A!5$]]<?3&D42O/&)K&M7D&,&Z57-1M))2T=VKQ1!X
M2R13!8_-%./UV//AE8OR9HI4)^KL1V:B3F:14@9:5; U/:YK0 !KLJ=%-:"*
M\@.V0]@@2>V>&'>MC3!0Y#["EH)W*I- $/%!R;&XRI:8@VI=H=7ZQV'P<S7%
M3DVEZA4KGLJ3O9ZM17PM8J$K0DDF">ZD(A5* M0W@AW2Y<78LT1M*G3QK"BV
MJHK5:W()E6*1&O''%P;_@-RBG^>29^#H! /RGU=J:YE"9*;22[TBV8]$]>7B
M:XO<M.N[4!95J=+6D!A>Q=XY-1>W%"QL+1V7E6OLU>F_U.M-&R18G6YA@3EI
ML%R)E7S!G?CZ^H/.DZ@_Z/S8M_W"Y!52I:;UE2Y\CXW]C9Q1:X,03SLST"6=
MU'(7K0Q.SF+DP@B2P"BI+.D\!67.^ 13075)KR"Z^W!)0H+2.8OJ5&H_(ZJA
MW%3$^/JD]>(FM5[DN1&,3)H[UE57RU->:M&(85"=3.V4KUS'Q08PXO?QQ(UH
MXMKP'XF%6])%._=?SS=/*?+7=(-KG;58LQ@Q$(X]K[J3?2D3A-00*@U.B@8E
MR^-'PJJXOET!\!R3@[ Z1XK1P:_'?C$'S%\E[L\QQR%V)XF&>"+4K.XQ/3]/
M@+V4E0E6&-<\I@XWH2"&%"\F+W? [>7KE[J:($MRTB[\@'=2%))AD  ]HC(P
MQ#X\)Y$T!4;^Y,EEL^OJ:IEK]ZE#F>O4%!",=WUE;=S:%361M\5%<YT[5VH.
MZCVH2GJ*<<68KE0:=*!Y$:6G_4CWM:EIQ/J^UN]KM>N$T]9UXL<AG=N:_ZS)
M:*'G1-M3:(\4"I=8B>2'(ZVIJ<=0C9.6FR1I;NYKSISH\@OX=L6MS6I=MIVF
M&B52U/5H$JBQ>TQ5V)':S^2U,3JQ%3HO&?XFW+_55.L7#-YZILS-'<W-9<ZR
M\,='Z-XEO+6_#F_=,[RUM0YOM='GK6!Q^A_?#49_?W8=^/^WV]W'<*S_ZD'N
M!U,4S>G#Z>%[]^RM^^;DXO+\Y/7'RY.S]VM.STZ$5'''X+(QRK;A!2NRA%O@
MFK=H \R Z5TQ5BBE$F?R2-$D%,;9--"T*0:@N.\GHA'0*0'_]6A@5X#/A;8>
M)#:H;HAQ(&"Q")Q#UKXHX4? S0S($!8M6$]/AY%BJM].2CR8R +6B:S\-&ML
MJ@T$#[.WCZ)XB%!7CEU=7!O<6"2^L%(R:3(-OS.UTT8<PY(>G(V[CC]GVW_>
MA&XI2O5/53:)1ZES@_:,>969^KKTPSJ'\VMF$*,O'-,C!DG\29%+KE11GXQ/
M^X/ OD+\H\T1.LH35RH#IAK;NJX&L:;:AZ':08@LGSCV0HJDG"6#<8A9#E5Y
M?RII+MC''MFR:7DO8#J27?!I8M6D='D&E(8?1,-@!K()<9 L:'QNDF5?G/5%
M6%^$![@(ID($HQ7*U%^B3B%F^,(T*BX]3$$&+!L]',9YE*WI=4VO#U(RPBCJ
MDE8VR'6;J";W."?7",^U$./Z)6LR79/I0[!5-O_"N6W3V6KPFN[6=/< =)>J
M+ M-)?-T CHGNQO6]+:FMP>@-T2*V,9]-J%,Y+)J*%AN_PKA148R-WBUC(7E
M6]E9$6)0"!-(Z52VX<6(\V"&<4KM,T/<K'YHOJ;Z-=4_ -5K*D<RUF53L 5H
MB?G&,Y-,R&[FB1IQ(Q#KPF#Z'T-2]3LQKBF_-(JNC5I;D_2:I!_"KBJWX>5:
M&IR_RO$#8L# S=?5(-<D^%"FO0[(,<E9]=5+58(*(S[T;QZY[..W%ZV=^G.'
M6DZ1HF5I4XQJ/L]#J7;3V]XNATG59ZD>RP%:79V./BE*YI1+RGAN *SDV@]"
M/!#/A<=9V/F1HW_#[9LI53]?=UQZ7=:<J:L[(::<%J690\%^DI"J,#;J!JO@
M::&#QX*7#68^PTG),.RXE1&YGL=022-(J96=%GW5HBQUN..\3_IX78W?P.)@
MP5CZ$I0\RL/,"ICH%$T3[B,A8PA((P'L)YZ3HV_*L^"4TL+#XF$(QJ3R^-@N
MC08!BX-R1],<> <K:)3N4*(\3T/DA[Y4A8IHFL-RC5JI&8YC<)<IWQG">0()
ME&*@Q<X1A+E2%NCMR?OS0^NN]7M4?BL:U>9@AX>L6?@$4LAG%/:'?XWBF\BY
MXT __!4[H3R/2,H;%@8I4*A&J5M\D? <DJC,59D"*>32>AD)3,0Y-4U*/P]9
M,9'-O355/1PLRQ=D>:E."-<A<;,\B80W<#DGX^AQZRO0-!6#%"6J,I/"FR7!
M2EK;'%$Z^525<"=.G=DTR0^> W6L46$@*=EI:2*P'\,P3@D K_$[]"LS"8+9
MA['/%1T).U19#5WZ!N^"WA2<GX[2ED:_!4M#:[(.CHVPXEAJ!^C<>H"N?8#X
M/5=?*\%UK%*6UD;Q6=M)E;*G5/R)U/+2Z,[BP<MLE5.A=!&X"@_DD>UCK0UV
MRTH=*0B%9V#K;96AW WDSX8AE],DX?%$C;$ *8]O;?[S'YY]M9(QUG&HB=S4
ME.'4;KA$Z?86)&[TJRI,HU9' OZ0,I*DN*'? ]ZN2T?BC=#99\J/J/Q<8]G#
MH,Y\V:_'R@CP9OJ3"D]XNJ*C44)$,>%*#C7*M-<J.$2LWS4.,HT&E !VG4=J
M!4.71IPV;H!9.;>.;5:.&I5AASJ,MQX=%>D((JJP.J(^KI*'/'=',>D<4L9C
M3@ZG3#%GHMJ0Z%:="D:=AM:Y19Z W;GQ*E"1_.4YTIK55!7DE$H.IE89[OJ^
M%71CL^@@#)T!53*6I 3MP6/#B#@LU=X<JHCHBO5QKBW+U!J,BY0()AK+N.5Z
MGY6BD95,U"([SJ'')<^T/EO!QKJ"C;6RU&G^4A":Z(T(C4K&E1?R9PZ;11YY
M5-MI +GPQ:1Y%FPV5NU%GIAE,Q;OE'1AV0NB99 5QFQDQ3@5Y5:RZ)\"63X!
MXOQ8)1M33=2QJXDN*&GKV8Q FYMRLB6$A3#-.G%I:DJ#:1X"[U%QGH9S>1=:
M)0*HUBG9V U77Z)RF3Y64ZWB^=I"M!>HN)BP(@=1$(\\:G!7E"H^-^OF-;[S
MT(B*$\<: -,PK'[/I856[EBKIJ_KF:?YX-\R?VN:];S,VLX[=ZT :]5':EI=
M81D4'0XS^!?WH"T07H2[MVT$WFHIHJ'SS!OL^9(;B"F%.H?3#L"IXIMF@7YO
M6<TK;G%16+Y9=2G+0)+!,L](L036A@4ZJV?SIM&P #)Z)0J/@I]Q):L@3O0,
M*+5 JP!(RQO%]@[FM1J^EDMLK]_JZ7H(O;1!_-TE3^M@G:=USSRM[76>UO+R
MM Y6DZ=U>OSKX:G[[O#R\OC\8IV@Q7IJM4\!5Q=P2OS>U463VKP 1K+-L!(,
M:(<S*4>?$TKX5[ WHH%*KK"7#7# *VQE\\'#!?$N_!$GG^#//QY<1;.HX3X4
MVNNNAD*/_^?#\?GEFC:%-@MO$5D)7$>EJ%NM1@YIG652'* O"0D5^;'([\,H
M KL!-"%,J4#+_BWP?IC^YC^-OHB%BESV);U1H.HA@FBKY[G];G_;LG#2N#0!
MU!X3Q;+?,1X#&F5#EVFF\C@IVS>ST(_\+$[F&%D!.]R?H3:+VEG11Z=:\\<J
MXHXO"Z)<<3FRJYB="MA%)V*5-AV"3LK[\AZ3QGL#4VR_82^?XZ7_)]AQ*IQB
MSP]_.GM9_.WITC^PS _Y -14T%K(8>'C.6R<I$GGN8>!!=XM+'&"+_R H*H;
MK$L] ;5>'<584CIU3B)I!T2%L*F[.<9?L$,?[/I,T?';%N2,QY3L $JJA!$\
M]PHTNDB[9_P\FYBT_11K>](T?,3"P+!$+_#0*-#U#YWB?4^6V_16PVU^_^WX
M_-C]X^RC>W3X'@,_;]QW9_#)R?NW9^<@)M=IS#0%,%OH_H\#K";AEUP2CKE,
MFJM(<YK-7A$FNC@^:C4"^/$FJ[;!_5[G=EQ%S:G[X^$IF6]*05P.#9:\*6;J
M7E'.1;B57=^([2OYB1T=K;IG'.N%:3Q5.G^-C#R>5<%'8\%IM"1AP)89_M=H
MZW:X71B+A*D_4GIS'-N23 L7 75E3HN>/Q',FEP9MC.4[=51/,RGS(Q@WQ.V
M)!LD#?K%<=,BA9%=/PE":2:D,FY5A@\43C#>LH#;L20JF]=$%8?'<Y$:M\^/
MPUC629.,F02#0%.1TWSB3\$5]JA3^"/.L0T/;+_/Q</PCL(V4O<&IS#N:RY(
MB\9-$6END@570TJTV,1[HP9I@)7S/J)*+-1A?&.!W&URO=^HJH-(^Y_L*\C:
M!<[-<GZV>XRXEI=^-1**O"'UI$2PI5I154 B,7M$"EW*NJSVDPVK+)2=RAB,
M4[#XR&UC%B53]>[K:)1#:Z!6@TD<(4P.;IW--ZPIZN:7M#E8G!GG"'O^2_!J
MDF6SGU^\N+FYZ0"C[5S%UUB?Z8>_%R#K**QMJCKZ^FP=V#_8-]PP("M0>=,.
M4#-NFH=TS_Q]#M>*0N-4JD,"ZKI%"? IA/-CW3JP,:](B4UC:CR']Q![,P]"
M+%R-[EYVB?KCC._8G'AI^=0=9GMX]@0"&.=)%*038M>>H88?_41!S_LMOE'7
M2BH>6K?,D>LJ[0(2.39IY,.A*>2-^G9+?R6M3E3%H>X%U\@N"QV@^C.<3NKX
M]%KI*11=JY0J*J83:G*#HR:8&A=+K-=F%10MD,JM(S7D"LP(71.';KV_KA;E
MFO5V'EW+_8H:6_WNVG=[3]_MSMIWNS3?;:^_&EOUY/W1V?F'LW.R2K'8UM'Q
M^>7AR7O;6'5?_^&>'[\%H_;]T?$J[O0=[?L5>\U0E?6QEE/J<GS+]'(U?BO'
MMCPT(*?,5.OX*ZG8C6 =09M@.VBXQ8AC(9!>,$6MSZ=N%,6[X$VH%^@AJ84?
M?I#%8"15+!H6Z:E"[Q@E0Y<T.T+#E%XML["65C:J" / [60,)*=%?G6<UXJ+
M8\,+&?)D^A50F,]Z+8J4<9[EB=)&0VFB7DW(\3S0=T?Z:CX;D?>0P[FX=>6W
M$2)N&H_@G"E-+$</FAHIMJM+%<TJQR;M?TK]_19X#NS3).4-B,L-X_@3I4J&
MIJRY91[=OND4=]6]D 74;<IT6G[<)@T"54[L0ZL) AL*!80.<$H+*@U8N!5H
MSP+> +-KH^]:":QQ@ KE%;M6]8TCBD'V.75"=+OJEE!TQ,6N%H?@%CJWIHL'
M* =WOWU<IVD]\30MY):U" PH$1.@Q;\_JUOB+PY!<P_ !GBA1E=^\@)XI?^B
MU]ON]?>W7W2[W5ZWM[6WV^_OP#_[.[T7RN_VM[9W]GJ;O>ZG_^N+=3K)IL]>
MF3@/ZBC2ZT'LE#%(+9C1HKB/UT#N./=W/DS0Q>_AJ9W5Y=>N[\ W?0?^.Z?B
MZ<!%S360S?B*N]#O;1UT@0J[VWU8(MV%[5YOMP]WX<_FN_#?Y;OP)\]*[@"3
MMER G5;ZG[N]K37UKZG_'M1_E"<):G1,^]B1AB9!5+F/@?A&4EO*U>@>[![L
MT-7H'^QM;75[F_M5.:$&"=R#.4U)^#I>$\HY*=J"E*>3?NE\>EL[VR*VN@=;
M79B-WULP'WW5<$+/7RYO#GO;>@[[6ZT[@J/3+/0,EC4!>-_!%D^@?W"P79L
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M9!0<*P"]M]-CS@-7+R0U[EC%EC]F+[R@7;D!&H P6@!!F)Y%)>;!A;_R=%:
MZQ[U X*UF5Q^AF&'KAWVZ63\&)N)B0$!.+3$@04N+M3$6G">-D1-=LH+(S>T
M26?7^&.'HZV@QP+)&4?,3X0,'9$E&E=F\J$E=D0-B7 ^VQWA.GN@'&IPX.K>
M.(!8GTP ??9H]<.^F!=W[-$9]MD3FB8DU,06AZX,OTO CXB/PU-3$4I]RR<O
MR"#T_) )?GP;VES@7;E8/FQ+\F=U\QGW2Z8-NDL_<;"XRP&&6"7NWW$!QCRT
ML "F%/4W8R"@-A>-'6]3C#0!%Q@06-1_27JUQX,-/W!.3QE 'HGDR5=CV)X"
M7'NJOGM4?=UD/2EX($)[:/]+4C["2\ 61%85_#K  N0 UB9"J=4.Z4$D-8!6
M0\L-?2"\\%O'=OT8\Z>0>B NJ;DE L),?MCII98R<Z!?Y/59[X"T /GGYC].
MK'?YZ-N>.P+>Y-&7@A8.F,<>/#;H^1I*5,812('YZ"-^1HH1_6TE)2[0#90\
M9KJ1K15H>_<Y8VW2!#M# P&!+^C!\257"9.F_(4>Q1JG""B<9MP$0]Y6JW$N
MAN-)#3U)6R/1LD3:DOKK]-!,2YF-1W$[XDL0-,4'.DW4KE*VX:11^!FNN;<-
M[)AMH+A>LQ0+\E' ,\#Y /$(R14'&M.W'&4PL"W6MFSLK4!VJ@Q%*J]Q!D2(
M*-%45/5[(&DB:IN8/*#PG&D.K'@*T2.7"HF' D4SY#?IRA%$")^)) ^4]W!!
MB9=8($@:"&5\RGH$68+'@<:V70<$7Z"1\:!2B-ZCXJZA8FGM>F/?!70AA2*%
M#< ?^IPY"/&S&"$BJF0_"8 7=KQ$VH-0;& RX(Z SKX+R@\3&9("Z2-9/(E+
M6P#NR7_WH#\7Z)<WG@L]SX&0>I-14"9!>I(E3>C/S^O*H/2#,!D(?'L!8R(9
M7^!)7G.100@U.?M5M"C83\2?G.0"2OI[%"H3[\=+YVKQ),S"8:"H./YZ/3^%
MHT6;<<R)P(8IVV.^H@!DA+("E*F[U+,Y1%5%F*LB,H1M00K:C=0G\IK4(:3^
MX+B)D=&E($3ZZ7I.XLYH "N^D-D*4CRX*2- TZ(V&9+H9&9)X%+66/3Z1I9M
MY_%D$61B.!7Z"!,B"8R F@M&1Y+XPFRT(&)W%J7G19< MQUBVALWR4#6=TU
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M1YK2KM!4,_0$MG>X0MSR2,:4U=#+85T(^4#"QW[([@L%K:1YS!(JT#<4*C*
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MNT>.YQ@9/FFWO]EA'RS4W6<7/-,OK_E_ODY\@SZ<MU_2TP?W_P!02P,$%
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MUDCR68"R3#G_7#/XW;"\^^*/=W4O]4MF[\%9]LH-P+2I?P-02P$"% ,4
M"  "B.E:?Y$N(V$$   H#   $0              @ $     87-N<RTR,#(U
M,#,S,2YX<V102P$"% ,4    "  "B.E:'P;Z5@4%  !Y(@  %0
M    @ &0!   87-N<RTR,#(U,#,S,5]L86(N>&UL4$L! A0#%     @  HCI
M6H 9G'%G!   <!8  !4              ( !R D  &%S;G,M,C R-3 S,S%?
M<')E+GAM;%!+ 0(4 Q0    (  *(Z5KIC^^S4I,  $(8!  8
M  "  6(.  !E83 R-#@S-C4M<S%?86-T96QI<RYH=&U02P$"% ,4    "  "
MB.E:CSLR^*0&  !U.   '0              @ 'JH0  96$P,C0X,S8U,#%E
M>"UF965?86-T96QI<RYH=&U02P$"% ,4    "  "B.E:\VI7)E\"  !1!P
M'0              @ ')J   96$P,C0X,S8U,#%E>#(S+3%?86-T96QI<RYH
M=&U02P$"% ,4    "  "B.E:D1->IW@*  !W+P  '               @ %C
MJP  96$P,C0X,S8U,#%E>#4M,5]A8W1E;&ES+FAT;5!+ 0(4 Q0    (  *(
MZ5H"AN3SKQ,  )X4   -              "  16V  !I;6%G95\P,#$N:G!G
64$L%!@     (  @ )@(  ._)      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea0248365-s1_actelis_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="asns-20250331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141284</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <dei:DocumentType contextRef="c0" id="ixv-2975">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-36">Actelis Networks, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-47">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-149">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-156">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-164">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-2976">false</dei:EntityExTransitionPeriod>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-2979">0001141284</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-2980">false</dei:AmendmentFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
